As filed with the U.S. Securities and Exchange Commission on ~~April~~June 422, ~~2025~~2026.

Registration No. 333-[*]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM S-1

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

Tenon Medical, Inc.

(Exact name of registrant as specified in its charter)

Delaware	3841	45-5574718
(State or Other Jurisdiction of Incorporation or Organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification No.)
(State or other jurisdiction of incorporation or organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Number)

104 Cooper Court

Los Gatos, CA 95032

(408) 649-5760

(Address, including zip code, and telephone number, including area code,

of registrant’s principal executive offices)

Steven M. Foster

Chief Executive Officer and President

Tenon Medical, Inc.

104 Cooper Court

Los Gatos, CA 95032

(408) 649-5760

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Ross D. Carmel, Esq. Jeffrey P. Wofford, Esq. Sichenzia Ross Ference Carmel LLP 1185 Avenue of Americas, 31st Floor New York, New York 10036 Telephone: (212) 930-9700

Ross D. Carmel, Esq.	Richard A. Friedman, Esq.
Jeffrey P. Wofford, Esq.	Sean F. Reid, Esq.
Anna Chaykina, Esq.	Sheppard, Mullin, Richter & Hampton LLP
Sichenzia Ross Ference Carmel LLP	30 Rockefeller Plaza
1185 Avenue of Americas, 26^th Floor	New York, New York 10112
New York, New York 10036	Telephone: (212) 653-8700
Telephone: (212) 930-9700

Approximate date of commencement of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement.

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.

The information in this prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is not soliciting an offer to buy these securities in any state or other jurisdiction where the offer or sale is not permitted.

PRELIMINARY PROSPECTUS SUBJECT TO COMPLETION DATED ~~APRIL~~JUNE 422, ~~2025~~2026

1,812,987 shares of Common Stock

Common Stock Purchase Warrants to Purchase up to 6,975,584 shares of Common Stock

Pre-funded Warrants to Purchase up to 4,000,000 shares of Common Stock

Up to 6,975,584 shares of Common Stock underlying the Common Stock Purchase Warrants

Up to 4,000,000 shares of Common Stock underlying the Pre-funded Warrants

Tenon Medical, Inc.

5We are offering on a firm commitment basis up to 1,~~673~~812,~~550~~987 ~~Shares~~shares of our common stock, par value $0.001 per share, together with common stock purchase warrants to purchase up to 6,975,584 shares of common stock (the “Common ~~Stock~~Warrants”), at an assumed combined public offering price of $0.6021 per share of common stock and accompanying Common Warrants, based on the closing price of our common stock on The Nasdaq Capital Market, or Nasdaq, on June 17, 2026; provided however, if we effect a reverse stock split, the number of shares of common stock issuable under the Common Warrants will increase to 8,719,481 (on a pre-stock split basis).

~~This prospectus relates to the resale from time~~Each toCommon ~~time~~Warrant ofwill upbe toimmediately ~~5,673,550~~exercisable ~~shares~~on ofthe ~~common~~date ~~stock, par value $0.001 per share,~~ of ~~Tenon Medical, Inc~~issuance. ~~(the~~The ~~“Selling~~first ~~Stockholder Shares”)~~date byon ~~the~~which ~~selling~~each ~~stockholder identified in this prospectus (the “Selling Stockholder”), consisting~~ of: ~~(i) 2,445,700 shares of common stock issuable upon~~ the ~~exercise of Series C-1~~ Common ~~Stock~~Warrants ~~purchase~~are ~~warrants (the “Series C-1 Warrants”)~~exercisable ~~purchased~~shall bybe ~~the~~referred ~~Selling Stockholder in a private placement transaction pursuant~~ to ~~the~~herein ~~terms of a warrant exercise inducement offer letter agreement dated~~ as ~~of March 11, 2025 between us and~~ the ~~Selling Stockholder (the~~ “~~Inducement~~Initial ~~Letter~~Exercise Date”);. ~~(ii)~~The ~~1,222,850 shares of common stock issuable upon the exercise of Series C-2~~ Common ~~Stock purchase warrants (the “Series C-2~~ Warrants~~” and~~ ~~together~~have ~~with~~an ~~the~~exercise ~~Series~~price ~~C-1 Warrants, the “Series C Warrants”) purchased by the Selling Stockholder in a private placement transaction pursuant to the terms~~ of ~~the~~$[*] ~~Inducement~~per ~~Letter;~~ share (~~iii)~~100% ~~733,500 shares~~ of ~~common stock issuable upon~~ the ~~exercise of~~combined ~~Series~~public Doffering ~~common~~price ~~stock~~per ~~purchase~~share warrants (the “Series D Warrants”) purchased by the Selling Stockholder in a private placement transaction pursuant to a securities purchase agreement (the “Series D Purchase Agreement”) dated March 25, 2025 related to the Series D Warrants and (iv) 1,271,500 shares of ~~common~~our ~~stock issuable upon the exercise of Series E~~ common stock ~~purchase warrants (the “Series E Warrants”~~ and ~~together~~accompanying ~~with~~Common ~~the Series C~~ Warrants) and ~~the~~will ~~Series~~expire Dfive ~~Warrants, the “Warrants”) purchased by the Selling~~years ~~Stockholder~~from ~~in a private placement transaction pursuant to a securities purchase agreement (~~the ~~“Series~~Initial EExercise ~~Purchase Agreement”) dated March 25, 2025 related to the Series E Warrants~~Date. ~~The Series D Warrants and the Series E Warrants have five year terms and are exercisable at $2.00 per share.~~

We are ~~filing~~also ~~this~~offering ~~registration~~pre-funded ~~statement~~common ~~on Form~~stock Spurchase warrants (the “Pre-1funded Warrants”) to purchase up to 4,000,000 shares of ~~which~~common stock to those purchasers whose purchase of shares of common stock in this ~~prospectus~~offering ~~forms~~would aresult ~~part~~in the purchaser, totogether with ~~fulfill~~its ~~our~~affiliates ~~contractual~~and ~~obligations~~certain torelated ~~provide~~parties, ~~for~~beneficially owning more than 4.99% (or, at the ~~registration~~election of the ~~resale~~ purchaser, 9.99%) of our ~~the~~outstanding ~~Selling~~common ~~Stockholder~~stock ~~Shares~~immediately byfollowing ~~Selling~~the ~~Stockholder.~~consummation ~~See~~of ~~“Selling~~this ~~Stockholder”~~offering, ~~beginning~~in onlieu ~~page~~of 12shares of ~~this~~common stock that would result ~~prospectus~~in ~~for~~beneficial ~~more~~ownership ~~information~~in ~~about~~excess of 4.99% (or, at the ~~Selling~~election ~~Stockholder~~of the purchaser, 9.99%) of our outstanding common stock. The ~~registration~~purchase price of ~~the~~each ~~shares~~Pre-funded ofWarrant ~~Selling~~and ~~Stockholder~~accompanying ~~Shares~~Common Warrants will be equal to ~~which~~combined public offering price per share and accompanying ~~this~~Common ~~prospectus~~Warrants ~~relates~~minus ~~does~~$0.0001. ~~not~~Each ~~require~~Pre-funded Warrant will be immediately exercisable for one share of our common stock and has an exercise price of $0.0001 per share. The Pre-funded Warrants will expire when exercised in full. Each Pre-funded Warrant is being offered together with the ~~Selling~~Common ~~Stockholder~~Warrants. toThe Pre-funded Warrants and Common Warrants are immediately separable and will be issued separately in this offering but must be purchased together in this offering. For each Pre-funded Warrant that we sell, ~~any~~the number of ~~their~~shares ~~Selling~~of ~~Stockholder~~common ~~Shares~~stock we are offering will be reduced on a one-for-one basis.

WeEach share ~~are~~of ~~not~~common ~~offering~~stock, ~~any~~or ~~Selling~~a ~~Stockholder Shares~~pre-funded ~~under~~warrant ~~this~~in ~~prospectus~~lieu ~~and~~thereof, ~~will~~is ~~not~~being ~~receive~~sold ~~any~~together ~~proceeds~~with ~~from~~one ~~the~~and ~~sale~~two ortenths ~~other~~(1.2) ~~disposition~~Common ofWarrants; provided ~~the~~however, ~~Selling~~if ~~Stockholder~~we ~~Shares. However~~effect a reverse stock split, wethe number of warrants will ~~receive~~be ~~the~~increased ~~proceeds~~to ~~from~~one ~~any~~and ~~exercise~~one-half (1.5) for each share of ~~the~~common ~~Warrants~~stock ~~for~~and/or ~~cash~~pre-funded warrant sold. ~~See~~The ~~“Use~~shares of ~~Proceeds”~~common ~~beginning~~stock onand Common Warrants are immediately separable and will be ~~page~~issued 11separately ofin this ~~prospectus~~offering but must be purchased together in this offering.

~~The Selling Stockholder identified in this prospectus,~~Pursuant orto ~~its~~the ~~pledgees,~~registration ~~assignees~~statement, ~~donees,~~of ~~transferees~~which orthis ~~successors-in-interest,~~prospectus ~~from~~forms ~~time~~a ~~to time may offer and sell through public or private transactions at prevailing market prices~~part, atwe ~~prices~~are ~~related~~also toregistering ~~prevailing market prices or at privately negotiated prices~~ the shares ~~held by them directly or through underwriters, agents or broker-dealers on terms to be determined at the time~~ of ~~sale,~~common asstock ~~described~~issuable ~~in more~~upon ~~detail~~exercise ~~in this prospectus. See “Plan~~ of ~~Distribution” beginning on page 13 of this prospectus for more information about how~~ the ~~Selling~~Common ~~Stockholder~~Warrants, ~~may sell its Selling Stockholder Shares. The Selling Stockholder may be deemed an “underwriter” within~~ the ~~meaning~~Pre-funded ofWarrants, ~~Section~~and ~~2(a)(11) of~~ the ~~Securities~~Underwriter’s ~~Act of 1933, as amended~~Warrants.

WeOur common ~~have~~stock ~~agreed,~~is ~~pursuant~~listed toon The Nasdaq Capital Market under the ~~terms~~symbol “TNON.” The last reported sale price of ~~the~~our ~~Inducement~~common stock ~~Letter,~~on ~~the~~The ~~Series~~Nasdaq DCapital ~~Purchase~~Market ~~Agreement~~on ~~and~~June ~~the~~17, ~~Series~~2026 Ewas ~~Purchase~~$0.6021 ~~Agreement~~per toshare. ~~bear~~The ~~all~~actual ofcombined ~~the~~public ~~expenses~~offering inprice ~~connection~~per ~~with~~share ~~the~~and ~~registration~~accompanying ofCommon ~~the~~Warrants ~~Selling~~will ~~Stockholder~~be ~~Shares~~determined ~~pursuant~~between toWallachBeth ~~this~~Capital ~~prospectus.~~LLC ~~The~~as ~~Selling~~underwriter ~~Stockholder~~(“WallachBeth” ~~will~~or ~~pay~~the or“underwriter”) and ~~assume~~us ~~all~~at ~~commissions,~~the ~~discounts, fees~~time of ~~underwriters~~pricing, ~~agents,~~considering ~~selling~~several ~~brokers~~factors oras ~~dealer~~described ~~managers~~in “Underwriting - Pricing of the Offer” and ~~similar~~may be ~~expenses,~~at ifa ~~any~~discount to the current market price. Therefore, ~~attributable~~the toassumed ~~their~~public ~~respective~~offering ~~sales~~price used throughout this prospectus may not be indicative of the ~~Selling~~final ~~Stockholder~~offering ~~Shares~~price.

~~Our~~We do ~~common~~not ~~stock~~intend isto ~~listed~~apply onto ~~The~~list ~~Nasdaq~~the ~~Capital Market~~Common ~~under~~Warrants ~~the~~or ~~symbol~~Pre-funded ~~“TNON.”~~Warrants ~~The~~on ~~last~~any ~~reported~~national ~~sale~~securities ~~price~~exchange ofor ~~our~~other ~~common~~nationally ~~stock~~recognized trading onsystem. ~~The~~Without ~~Nasdaq~~an ~~Capital~~active ~~Market~~trading onmarket, ~~April~~the ~~1, 2025~~liquidity ~~was~~of ~~$1.69~~the ~~per~~Common ~~share~~Warrants and Pre-funded Warrants will be limited.

~~Investing~~We intend into ~~our~~use ~~securities~~the ~~involves~~proceeds ~~a high~~from ~~degree~~this offering for expansion of ~~risk.~~the ~~See~~commercial ~~“Risk~~footprint ~~Factors”~~of ~~beginning~~our product portfolio including training clinicians on ~~page~~our 7current ofprocedures, ~~this~~hiring ~~prospectus~~additional ~~for~~direct asales ~~discussion~~reps, expansion of ~~information~~our external distribution network, continuing clinical research ~~that~~studies ~~should~~to besupport ~~considered~~reimbursement inand ~~connection~~coverage ~~with~~efforts, anfunding ~~investment~~research inand ~~our~~development ~~securities~~including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes. See “Use of Proceeds.”

Investing in our securities involves a high degree of risk. See “Risk Factors” beginning on page 8 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

Neither the Securities and Exchange Commission (“SEC”) nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

We are an “emerging growth company” as that term is used in the Jumpstart Our Business Startups Act of 2012, and we have elected to comply with certain reduced public company reporting requirements.

The date of this prospectus is , 2025

Per Share
And
Accompanying
Common
Warrants

Per
Pre-funded
Warrant and
Accompanying
Common
Warrants

Total

Public offering price

Underwriting discount⁽¹⁾

Proceeds, before expenses, to us⁽²⁾

(1)	Represents a cash fee equal to 6.5% of the aggregate purchase price paid by investors in this offering. We also agreed to reimburse the underwriter for certain of its offering-related expenses, including its accountable expenses of up to a maximum of $65,000 and non-accountable expenses of 1% of the offering proceeds. See Underwriting” beginning on page 19 of this prospectus for a description of the compensation to be received by the underwriter.

(2)	The amount of offering proceeds to us presented in this table does not give effect to any exercise of the Common Warrants or Pre-funded Warrants.

We have granted the underwriter a 45-day option from the date of this prospectus to purchase up to a total of an additional [*] shares of common stock at $[●] per share, and/or [*] Common Warrants at $[*] per warrant, or any combination of additional shares of common stock and Common Warrants, less, in each case, the underwriting discounts and commissions, to cover over-allotments, if any.

We anticipate that delivery of the securities against payment therefor will be made on or before [*], 2026.

WallachBeth Capital LLC

The date of this prospectus is , 2026.

TABLE OF CONTENTS

ABOUT THIS PROSPECTUS	ii
MARKET DATA	ii
PROSPECTUS SUMMARY	1
SUMMARY OF THE OFFERING	6
RISK FACTORS	78
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS	913
USE OF PROCEEDS	1114
SELLING STOCKHOLDER	12
DILUTION	15
PLAN OF DISTRIBUTION	13
DESCRIPTION OF SECURITIES WE ARE OFFERING	16
EXPERTS	15
UNDERWRITING	19
LEGAL MATTERS	15
EXPERTS	22
WHERE YOU CAN FIND MORE INFORMATION	15
LEGAL MATTERS	22
INCORPORATION BY REFERENCE	16
INCORPORATION OF CERTAIN INFORMATION BY REFERENCE	22
WHERE YOU CAN FIND MORE INFORMATION	23

You should rely only on the information contained in this prospectus or any prospectus supplement or amendment. Neither we, nor the ~~placement agent~~underwriter, have authorized any other person to provide you with information that is different from, or adds to, that contained in this prospectus. If anyone provides you with different or inconsistent information, you should not rely on it. Neither we nor the ~~placement~~underwriter ~~agent~~ take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. You should assume that the information contained in this prospectus, or any free writing prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. We are not making an offer of any securities in any jurisdiction in which such offer is unlawful.

No action is being taken in any jurisdiction outside the United States to permit a public offering of our securities or possession or distribution of this prospectus in that jurisdiction. Persons who come into possession of this prospectus in jurisdictions outside the United States are required to inform themselves about and to observe any restrictions as to this public offering and the distribution of this prospectus applicable to that jurisdiction.

ABOUT THIS PROSPECTUS

Throughout this prospectus, unless otherwise designated or the context suggests otherwise,

●

all references to the “Tenon,” the “Company,” the “registrant,” “we,” “our,” or “us” in this prospectus mean Tenon Medical, Inc.;

●

“year” or “fiscal year” means the year ending December 31^st;

●

all dollar or $ references, when used in this prospectus, refer to United States dollars; and

●

all common stock and per share of common stock information in this prospectus gives effect to a one for eight (1:8) reverse stock split of our common stock, which became effective as of September 6, 2024.

Market Data

Market data and certain industry data and forecasts used throughout this prospectus were obtained from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. To our knowledge, certain third-party industry data that includes projections for future periods does not consider the effects of the worldwide coronavirus pandemic. Accordingly, those third-party projections may be overstated and should not be given undue weight. We have not independently verified any of the data from third party sources, nor have we ascertained the underlying economic assumptions relied upon therein. Similarly, internal surveys, industry forecasts and market research, which we believe to be reliable based on our management’s knowledge of the industry, have not been independently verified. Forecasts are particularly likely to be inaccurate, especially over long periods of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any misstatements regarding the industry data presented in this prospectus, our estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading “Risk Factors” in this prospectus. and in the documents incorporated herein by reference, together with the other information set forth in this prospectus, the risks described in Part I, Item 1A, Risk Factors in our most recent Annual Report on Form 10-K and in the other documents that we include or incorporate by reference into this prospectus. We are, however, liable for the information in the prospectus related to the market and industry data.

PROSPECTUS SUMMARY

This summary ~~provides~~highlights aselected ~~brief~~information ~~overview~~that ofis ~~the~~presented in greater detail elsewhere, or incorporated by reference, in this prospectus. ~~key~~It ~~aspects~~does not contain all of ~~our~~the ~~business~~information that may be important to you and ~~our~~your ~~securities~~investment decision. ~~The~~Before ~~reader~~investing in our securities, you should carefully read ~~the~~this entire prospectus ~~carefully~~, ~~especially~~including the ~~risks~~matters ofset ~~investing~~ forth in ~~our~~the ~~common~~section ~~stock~~titled ~~discussed under~~ “Risk Factors.” and the financial statements and related notes and other information that we incorporate by reference herein, including our Annual Report on Form 10-K. Some of the statements contained in this prospectus, including statements under “Prospectus Summary” and “Risk Factors” as well as those noted in the documents incorporated herein by reference, are forward-looking statements and may involve a number of risks and uncertainties. Our actual results and future events may differ significantly based upon a number of factors. The reader should not put undue reliance on the forward-looking statements in this document, which speak only as of the date on the cover of this prospectus.

The Company

The Company was incorporated in the State of Delaware on June 19, 2012 and was headquartered in San Ramon, California until June 2021 when it relocated to Los Gatos, California. The Company is a medical device company ~~that~~dedicated to transforming care for patients with certain sacro-pelvic disorders. The Company currently offers two systems to treat a diseased sacroiliac joint (the “SI Joint”). The Company has developed The Catamaran®™ SI Joint Fusion System (“The Catamaran System”) that offers a a novel, less invasive approach to the ~~sacroiliac joint (the “~~SI Joint”) using a single, robust, titanium implant for treatment of the most common types of SI -Joint disorders that cause lower back pain. The Company received U.S. Food and Drug Administration (“FDA”) clearance in 2018 for The Catamaran System and is currently focused on the US market. The Company’s products are subject to ongoing FDA regulatory requirements, including requirements related to manufacturing, labeling, marketing, adverse event reporting and recordkeeping. Since the national launch of The Catamaran System in October 2022, the Company ishas been focused on three commercial opportunities: 1) ~~Primary~~primary SI Joint procedures, 2) ~~Revision~~revision procedures of failed SI Joint implants and 3) SI -Joint fusion adjunct to a spine fusion construct.

In August 2025, the Company acquired substantially all of the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry^+® SI Joint Fusion System (“The SImmetry⁺ System”) that treats disorders of the SI Joint through minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles-including joint decortication, bone graft placement, and rigid fixation-with the goal of achieving a true biological fusion across the SI Joint.

The Opportunity

We estimate that over 30 million American adults have chronic lower back pain. Published clinical studies have shown that 15% to 30% of all chronic lower back pain is associated with the SI- Joint. For patients whose chronic lower back pain stems from the ~~Sacroiliac~~SI Joint ~~(“SI-Joint”)~~, our experience in both clinical trials and commercial settings indicates the system to be introduced by Tenon could be beneficial for patients who are properly diagnosed and screened for surgery by trained healthcare providers.

In 2019, approximately 475,000 patients in the United States were estimated to have received an aesthetic injection to temporarily alleviate pain emanating from the SI- Joint and/or to diagnose SI- Joint pain. Additionally, several non-surgical technologies have been introduced in the past 10 years to address patients who do not respond to conservative options, including systemic oral medications, opioids, physical therapy and injection therapy.

To date, the penetration of a surgical solution for this market has been relatively low (5-7%). We believe this is due to complex surgical approaches and suboptimal implant design of existing options. The penetration of this market with an optimized surgical solution is Tenon’s focus.

We believe the SI- Joint is the last major joint to be successfully addressed by the spine implant industry. Studies have shown that disability resulting from disease of the SI- Joint is comparable to the disability associated with a number of other serious spine conditions, such as knee and hip arthritis and degenerative disc disease, each of which has surgical solutions where an implant is used, and a multi-billion-dollar market exists.

The SI- Joint

The SI- Joint is a strong weight bearing synovial joint situated between the lumbar spine and the pelvis and is aligned along the longitudinal load bearing axis of the human spine when in an upright posture. It functions as a force transfer conduit where it transfers axial loads bi-directionally from the spine to the pelvis and lower extremities and allows forces to be transmitted from the extremities to the spine. It also provides load sharing between the hip and spine to contribute towards attenuation of impact shock and stress from activities of daily living.

The SI- Joint is a relatively immobile joint that connects the sacrum (the spinal segment that is attached to the base of the lumbar spine at the L5 vertebra) and the ilium of the pelvis. Each SI- Joint is approximately 2-4mm wide and irregularly shaped.

Motion of the SI- Joint features vertical shear and rotation. Although the rotational forces about the SI- Joint are relatively low, repetitive motions created by daily activities such as walking, jogging, twisting at the hips, and jumping can increase the stresses on the SI- Joint. If the SI- Joint is compromised through injury or degeneration, the load bearing and motion restraints from the surrounding anatomical structures of the SI- Joint will be compromised resulting in abnormal stress transfers across the joint to these structures, thereby further augmenting the degenerative cascade of the SI- Joint. Eventual pain and cessation of an individual’s normal activities due to a painful and unstable SI- Joint have led to an increase in the recent development of SI- Joint stabilization devices.

Non-Surgical Treatment of Sacroiliac Joint Disease

Several non-surgical treatments exist for suspected sacroiliac joint pain. These conservative steps often provide desired relief for the patient. Non-surgical treatments include:

● Physical Therapy. ● Drug Therapy: including opiates and non-steroidal anti-inflammatory medications.

●

Intra-Articular Injections of Steroid Medications: which are typically performed by physicians who specialize in pain treatment or anesthesia.

● Radiofrequency Ablation: or the cauterizing of the lateral branches of the sacral nerve roots.

When conservative steps fail to deliver sustained pain relief and return to quality of life, specific diagnostic protocols are utilized to explore if a surgical option should be considered.

Diagnosis

Historically, diagnosing pain from the SI- Joint was not routinely a focus of orthopedic or neurosurgery training during medical school or residency programs. Due to its invasiveness, post-operative pain, and muscle disruption along with a difficult procedure overall, the open SI~~-Joint~~ Joint fusion procedure was rarely taught in these settings.

The emergence of various SI-Joint surgical technologies has generated a renewed discussion of SI-Joint issues. Of particular focus is the diagnostic protocol utilized to properly select patients for SI-Joint surgery. Patients with low back pain typically start with primary care physicians who often refer to pain specialists. Here, the patient will undergo traditional physical therapy combined with oral medications (anti-inflammatory, narcotic, etc.). If the patient fails to respond to these steps the pain specialist may move to therapeutic injections of the SI-Joint. These injections may serve to lessen inflammation to the point that the patient is satisfied. However, the impact from these injections is often transient. In this case the patient is often referred to a clinician to determine if the patient may be a candidate for surgical intervention. A series of provocative tests in clinic, combined with a specific injection protocol to isolate the SI-Joint as the pain generator is then utilized to confirm the need for surgical intervention. Published literature has shown this technique to be a very effective step to determine the best treatment to alleviate pain.2

The emergence of various less invasive SI Joint surgical technologies has generated a renewed discussion of SI Joint issues. Of particular focus is the diagnostic protocol utilized to properly select patients for SI Joint surgery. Patients with low back pain typically start with primary care physicians who often refer to pain specialists. Here, the patient will undergo traditional physical therapy combined with oral medications (anti-inflammatory, narcotic, etc.). If the patient fails to respond to these steps the pain specialist may move to therapeutic injections of the SI Joint. These injections may serve to lessen inflammation to the point that the patient is satisfied. However, the impact from these injections is often transient. In this case the patient is often referred to a clinician to determine if the patient may be a candidate for surgical intervention. A series of provocative tests in clinic, combined with a specific injection protocol to isolate the SI Joint as the pain generator is then utilized to confirm the need for surgical intervention. Published literature has shown this technique to be a very effective step to determine the best treatment to alleviate pain.

Limitations of Existing Treatment Options

Surgical fixation and fusion of the SI- Joint with an open surgical technique was first reported in 1908, with further reports in the 1920s. The open procedure uses plates and screws, requires a 6 to 12-inch incision and is extremely invasive. Due to the high invasiveness and associated morbidity, the use of this procedure is limited to cases involving significant trauma, tumor, etc.

Less invasive surgical options along with implant design began to emerge over the past 15 years. These options feature a variety of approaches and implant designs and have been met with varying degrees of adoption. Lack of a standard and accepted diagnostic approach, complexity of approach, high morbidity of approach, abnormally high complication rates and inability to radiographically confirm fusion have all been cited as reasons for low adoption of these technologies.

Commercialization

Tenon’s Catamaran ~~initiated~~and ~~its~~SImmetery+ ~~national~~Systems ~~commercial~~make ~~launch of~~up ~~The~~the ~~Catamaran~~Company’s ~~System~~growing inportfolio ~~October~~of ~~2022~~advanced toSI ~~address~~Joint ~~what~~technologies. weTogether, these ~~believe~~platforms isuniquely aposition ~~large~~Tenon ~~market~~with ~~opportunity.~~multiple ~~The~~surgical ~~Catamaran~~approaches ~~System~~– ~~includes~~lateral ~~instruments~~ and ~~implants~~inferior-posterior ~~designed~~– both designed to ~~prepare~~be minimally invasive, enable authentic arthrodesis and ~~fixate~~supported by robust clinical evidence, including the published prospective Mainsail™ and EVoluSIon™ SI- Joint fusion studies. We anticipate that these differentiated technologies will enable physicians to customize treatment plans for their patients with an innovative portfolio that spans SI Joint, spinal fusion, and deformity adjuncts — each solution engineered to deliver fusion outcomes more reliably. ~~The~~We ~~Catamaran~~believe ~~System~~that isthis ~~distinct~~multi-platform, ~~from~~multi-approach ~~other~~strategy strengthens Tenon’s competitive ~~offerings~~ advantage in the ~~following~~expanding ~~ways:~~SI Joint fusion market and underscores the Company’s commitment to delivering effective, durable outcomes for physicians and patients.

●The Catamaran ~~Transfixes the SI-Joint~~System

●Tenon initiated ~~Inferior~~its /national ~~Posterior~~commercial ~~Sacroiliac~~launch ~~Fusion~~of ~~Approach~~The Catamaran System in October 2022 to address what we believe is a large market opportunity. The Catamaran System includes instruments and implants designed to prepare and fixate the SI Joint for fusion. The Catamaran System is distinct from other competitive offerings in the following ways:

● ~~Reduced~~Trans-articular ~~Approach~~placement ~~Morbidity~~across the SI Joint

● ~~Direct~~Inferior- ~~And~~posterior ~~Visualized~~sacroiliac ~~Approach~~fusion ~~to the SI-Joint~~approach

● ~~Single~~Reduced ~~Implant~~approach ~~Technique~~morbidity

● ~~Insertion~~Direct ~~Trajectory~~visualization ~~Away~~to ~~from~~ the ~~Neural~~SI ~~Foramen~~Joint

● ~~Insertion~~Single ~~Trajectory~~implant ~~Away from Major Lateral Vascular Structures~~technique

● ~~Autologous~~Insertion ~~Bone~~trajectory ~~Grafting~~away infrom the ~~Ilium,~~neural ~~Sacrum and Bridge~~foramen

● ~~Radiographic~~Insertion ~~Confirmation~~trajectory ofaway ~~Bridging~~from ~~Bone~~major ~~Fusion~~lateral ofvascular ~~the SI-Joint~~structures

●

Autologous bone grafting in the ilium, sacrum and bridge

●

Radiographic confirmation of bridging bone fusion of the SI Joint

The fixation device and its key features are shown below:

Key Features ~~“Pontoon”~~● inRobust single titanium implant ● Incorporates fusion principles to facilitate long-term fixation ● Immediate stabilization along the ~~ilium~~long ~~“Pontoon”~~axis inof the ~~sacrum~~joint. ● Fenestrated pontoons designed to facilitate bony in-growth. ● “Pontoons and Bridge window” filled with autologous bone from drilling process ~~Leading~~● ~~edge~~Proprietary osteotome ~~creates~~bridge ~~defect~~designed ~~and~~to ~~facilitates~~disrupt ~~ease~~the ofjoint ~~insertion~~in preparation for fusion

The Catamaran System represents a novel less invasive approach to treat SI Joint dysfunction. Its trans-articular placement, combined with a design rooted in fusion principles, ensures immediate fixation and stabilization supported by peer reviewed clinical and radiographic evidence of fusion with a compelling safety profile. The Catamaran System is a singular implant designed with several proprietary components which allow for it to be explicitly formatted to address the SI- Joint with a single, less invasive approach and implant. This contrasts with several competitive implant systems that require multiple approach pathways and implants to achieve fixation. In addition, the inferior-posterior approach is designed to be direct to the joint and through limited anatomical structures which may minimize the morbidity of the approach. The implant features a patented dual pontoon open cell design which enables the clinician to pack the pontoons with the patient’s own autologous bone designed to promote bone fusion across the joint. The Catamaran System is designed specially to resist vertical shear and rotation of the joint in which it was implanted, helping stabilize the joint in preparation for eventual fusion.

The instruments we have developed are proprietary to The Catamaran System and specifically designed to transfix the SI- Joint and facilitate an inferior-posterior approach that is unique to the system.

Tenon also has developed a proprietary 2D radiographic placement protocol as well as a protocol for 3D navigation utilizing the latest techniques in spine surgery. These Tenon advancements are intended to further enhance the safety and ease of the procedure and encourage more physicians to adopt the procedure.

In October 2022, we received Institutional Review Board (“IRB”) approval from WCG IRB for two separate Tenon-sponsored post market clinical studies of The Catamaran System. The approval by WCG allows designated Catamaran study centers to begin recruiting and enrolling patients into the clinical studies. The first approval from WCG IRB ~~will~~supports ~~support~~ a prospective, multi-center, single arm post market study that will evaluate the clinical outcomes of patients with sacroiliac joint disruptions or degenerative sacroiliitis treated with The Catamaran System. Patients will be followed out to 24 months assessing various patient reported outcomes, radiographic assessments, and adverse events. The second prospective, multi-center, Catamaran study will evaluate 6-to-12-month radiographic outcomes to assess fusion of patients that have already undergone treatment with The Catamaran System. In addition, retrospective and prospective clinical outcomes will be evaluated. ~~We anticipate completing enrollment by the end of the fourth quarter of 2025.~~

The SImmetry⁺ System

In August 2025, we acquired The SImmetry⁺ System, which affords an efficient and effective minimally invasive technique to effect a true arthrodesis of the SI Joint in the following way:

●

Minimally invasive lateral access for safety and control

●

System designed with well-established orthopedic fusion principles

●

New 3D printed titanium implants and proprietary instrumentation provides rigid fixation

●

Joint preparation with the proprietary SImmetry Decorticator removes cartilage and decorticates opposing joint surfaces

●

Bone graft delivery to the prepared joint to facilitate fusion

Corporate Information

We were incorporated on June 19, 2012 , in the State of Delaware. Our principal executive offices are located at 104 Cooper Court, Los Gatos, CA 95032. and our telephone number is (408) 649-5760. Our website address is www.tenonmed.com. The information on, ~~included~~or onthat can be accessed through, our website is not ~~part~~incorporated of by reference into this prospectus. We have included our website address as an inactive textual reference only.

Implications of Being an Emerging Growth Company

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”). We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act of 1933, as amended (the “Securities Act”); (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under applicable SEC rules. We expect that we will remain an emerging growth company for the foreseeable future, but cannot retain our emerging growth company status indefinitely and will no longer qualify as an emerging growth company on or before the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from specified disclosure requirements that are applicable to other public companies that are not emerging growth companies.

These exemptions include:

●

being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced “Management’s Discussion and Analysis of Financial Condition and Results of Operations” disclosure;

●

not being required to comply with the requirement of auditor attestation of our internal controls over financial reporting;

●

not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements;

●

reduced disclosure obligations regarding executive compensation; and

●

not being required to hold a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved.

We have taken advantage of certain reduced reporting requirements in this prospectus. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock.

An emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected to avail ourselves of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the dates on which adoption of such standards is required for other public reporting companies.

We are also a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and have elected to take advantage of certain of the scaled disclosure available for smaller reporting companies.

SUMMARY OF THE OFFERING

Shares of common stock offered by the Selling Stockholder:		Up to 5,673,550 shares of common stock, par value $0.001 per share, of Tenon Medical, Inc. by the Selling Stockholder, consisting of: (i) 2,445,700 shares of common stock issuable upon the exercise of the Series C-1 Warrants purchased by the Selling Stockholder in a private placement transaction pursuant to the Inducement Letter, at the exercise price of $1.25 per share and exercisable for five (5) years after the effective date of this registration statement; (ii) 1,222,850 shares of common stock issuable upon the exercise of the Series C-2 Warrants purchased by the Selling Stockholder in a private placement transaction pursuant to pursuant to the terms of the Inducement Letter, at the exercise price of $1.25 per share and exercisable for three (3) years after the effective date of this registration statement; (iii) 733,500 shares of common stock issuable upon the exercise of the Series D Warrants purchased by the Selling Stockholder in a private placement transaction pursuant to the Series D Purchase Agreement dated March 25, 2025 related to the Series D Warrants and (iv) 1,271,500 shares of common stock issuable upon the exercise of the Series E Warrants purchased by the Selling Stockholder in a private placement transaction pursuant to the Series E Purchase Agreement dated March 25, 2025 related to the Series E Warrants. The Series D Warrants and the Series E Warrants have five year terms and are exercisable at $2.00 per share.
Securities offered by us		1,812,987 shares of common stock, Pre-funded Warrants to purchase 4,000,000 shares of common stock, and accompanyingCommon Warrants to initially purchase up to 6,975,584 shares of common stock a, at an assumed combined public offering price of $0.6021 per share of common stock and accompanying Common Warrants. Each Common Warrant will expire 5 years from the Initial Exercise Date and have an exercise price of $[*] per share (100% of the combined public offering price per share of our common stock and accompanying Common Warrants); provided however, if we effect a reverse stock split, the number of shares of common stock issuable under the Common Warrants will increase to 8,719,481 (on a pre-stock split basis). This offering also relates to the shares of common stock issuable upon exercise of any Common Warrants sold in this offering. See “Description of the Securities We Are Offering -Warrants”.
Registration Rights:		Under the terms of the Inducement Letter, we agreed to file this registration statement with respect to the registration of the resale by the Selling Stockholder of the shares underlying the Series C Warrants by the 30th calendar day following the date of the Inducement Letter. Under the terms of the Series D Purchase Agreement, we agreed to file this registration statement with respect to the registration of the resale by the Selling Stockholder of the shares underlying the Series D Warrants by the 30th calendar day following the date of the Series D Purchase Agreement. Under the terms of the Series E Purchase Agreement, we agreed to file this registration statement with respect to the registration of the resale by the Selling Stockholder of the shares underlying the Series E Warrants by the 30th calendar day following the date of the Series E Purchase Agreement. In addition, we agreed to use commercially reasonable efforts to cause this registration statement to become effective within sixty (60) calendar days following the date of the Inducement Letter (or within 90 calendar days following the date hereof in case of “full review” of this registration statement by the SEC) and to keep this registration statement effective at all times until no holder of the Warrants owns any Warrants or Selling Stockholder Shares. See “Selling Stockholder” beginning on page 12 of this prospectus for more information about the Selling Stockholder. The registration of the shares of Common Stock to which this prospectus relates does not require the Selling Stockholder to sell any of their Selling Stockholder Shares.
Pre-Funded Warrants offered by us		We are also offering to those purchasers whose purchase of common stock in this offering would otherwise result in the purchaser, together with its affiliates and certain related parties, beneficially owning more than 4.99% (or, at the election of the purchaser, 9.99%) of our outstanding common stock immediately following the closing of this offering, in lieu of purchasing common stock, Pre-funded Warrants to purchase up to an aggregate of [*] shares of our common stock. Each Pre-funded Warrant is exercisable for one share of our common stock. The purchase price of each Pre-funded Warrant is equal to the price at which a share of common stock is being sold to the public in this offering, minus $0.0001, and the exercise price of each Pre-funded Warrant is $0.0001 per share. The Pre-funded Warrants are exercisable immediately and may be exercised at any time until all of the Pre-funded Warrants are exercised in full. This offering also relates to the shares of common stock issuable upon exercise of any Pre-funded Warrants sold in this offering. For each Pre-funded Warrant that we sell, the number of shares of common stock that we are offering will be reduced on a one-for-one basis. See “Description of the Securities We Are Offering - Warrants.”
Use of Proceeds:		The Selling Stockholder will receive all of the proceeds from the sale of the Selling Stockholder Shares offered from time to time pursuant to this prospectus. Accordingly, we will not receive any proceeds from the sale of Selling Stockholder Shares that may be sold from time to time pursuant to this prospectus; however, we will receive proceeds from any cash exercise of the Warrants. See “Use of Proceeds.” We intend to use the proceeds from the any cash exercise of the Warrants for working capital purposes.
Listing:		Our common stock and tradeable warrants (“Tradeable Warrants”) trade on The Nasdaq Capital Market under the symbols “TNON” and “TNONW,” respectively.
Risk Factors:		Your investment in shares of our common stock involves substantial risks. You should consider the “Risk Factors” included and incorporated by reference in this prospectus, including the risk factors incorporated by reference from our filings with the SEC.
Transfer Agent and registrar:		VStock Transfer, LLC.

~~Plan~~Common ofstock ~~Distribution:~~to ~~The~~be ~~Selling~~outstanding ~~Stockholder~~after ~~named~~the inoffering(1) ~~this prospectus~~17, ~~or their pledgees~~662,661 ~~donees,~~shares ~~transferees,~~(assuming ~~distributees,~~no ~~beneficiaries~~exercise orof ~~other successors-in-interest, may offer or sell~~ the ~~Selling~~Common ~~Stockholder Shares from time to time through public or private transactions at prevailing market prices~~Warrants, atno ~~prices~~sale ~~related~~of toPre-funded ~~prevailing~~Warrants ~~market~~and ~~prices~~no orexercise atof ~~privately negotiated prices. The Selling Stockholder may also resell~~ the ~~Selling Stockholder Shares to or through underwriters, broker~~over-~~dealers~~allotment ~~or agents, who may receive compensation in the form of discounts, concessions or commissions~~option).

Use of Proceeds

We currently intend to use the net proceeds to us from this offering for partial repayment of outstanding convertible notes, expansion of the commercial footprint of our product portfolio including training clinicians on our current procedures, hiring additional direct sales reps, expansion of our external distribution network, continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes. See the section of this prospectus titled “Use of Proceeds” beginning on page 14.

Listing		Our common stock and tradeable warrants (“Tradeable Warrants”) trade on The Nasdaq Capital Market under the symbols “TNON” and “TNONW,” respectively. There is no established public trading market for the Common Warrants and Pre-funded Warrants being sold in this offering and we do not expect a market to develop. In addition, we do not intend to apply to list the Common Warrants and Pre-funded Warrants on any national securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the Common Warrants and Pre-funded Warrants will be limited.
Risk Factors		You should carefully consider the information set forth in this prospectus and, in particular, the specific factors set forth in the “Risk Factors” section beginning on page 8 of this prospectus before deciding whether or not to invest in shares of our common stock.
Underwriter’s Warrant		The registration statement of which this prospectus is a part also registers for sale the Underwriter’s Warrants, which give the underwriter the right to purchase up to 3.0% of the shares of Common Stock (including any Pre-Funded Warrants) sold in this public offering, as a portion of the underwriting compensation in connection with this public offering. The Underwriter’s Warrants will be exercisable at any time, and from time to time, in whole or in part, and expiring five years from the date of the registration statement in this public offering at an exercise price of $[●] (120% of the combined offering price per share and Common Warrants). We are registering the Underwriter’s Warrants and the shares of common stock issuable upon exercise of the Underwriter’s Warrants in the registration statement of which this prospectus is a part. See “Underwriting-Underwriter’s Warrants” on page 20 of this prospectus for a description of the Underwriter’s Warrants

Lock-Up Agreements		We have agreed with the underwriter, subject to certain customary exceptions, not to sell additional equity securities for a period of 30 days after the effective date of this Offering, except that these restrictions shall not apply to any equity sales through an at-the-market facility. Our directors and officers have agreed with the underwriter not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common stock or securities convertible into common stock, subject to certain exceptions, for a period of 60 days after the date of this prospectus, which restriction may be waived in the discretion of the Representative. See “Underwriting-Lock-Up Agreements” on page 20 of this prospectus

Transfer Agent and registrar		Vstock Transfer, LLC.
Underwriter’s over-allotment option		We have granted the underwriter an option, exercisable within 45 days after the closing of this offering, to acquire up to an additional 15% of the total number of shares of common stock and/or Pre-funded Warrants, and/or Common Warrants to be offered by us pursuant to this offering, solely for the purpose of covering over-allotments, at the public offering price, less the underwriting discounts and commissions.

(1)	The number of shares of common stock to be outstanding after this offering is based on 11,849,674 shares of common stock outstanding as of June 17, 2026, and excludes:

●

8,173,914 shares of common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $2.11 per share;

●

17,697 shares of common stock issuable upon the exercise of outstanding stock options, with a weighted average exercise price equal to $13.12 per share;

●

1,213,692 shares of common stock issuable upon the vesting of restricted stock units (“RSUs”); and

●

42,841 shares of common stock reserved for future issuance under Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended.

RISK FACTORS

~~Before~~Investing in ~~purchasing~~our ~~any~~securities involves a high degree of ~~the~~risk. Before investing in our securities, you should carefully consider the ~~risk~~risks ~~factors~~described below ~~relating~~as towell ~~our~~as ~~company~~the ~~described~~risks ~~below~~set ~~and~~forth ~~incorporated~~under bythe ~~reference~~section intitled ~~this~~“Risk ~~prospectus~~Factors” ~~from~~ in our Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025 (the “Annual Report”), aswhich ~~well~~is incorporated by reference into this prospectus, as amended or supplemented by our subsequent filings with the ~~risks,~~SEC. ~~uncertainties,~~You ~~and~~should ~~additional~~also refer to the other information ~~set forth~~contained in ~~other~~this ~~documents~~prospectus and the documents incorporated by reference inherein, ~~this~~including ~~prospectus.~~our ~~For~~financial astatements ~~description~~and ofrelated ~~these~~notes ~~reports~~and the section titled “Management’s Discussion and ~~documents,~~Analysis of Financial Condition and ~~information about~~Results ~~where~~of ~~you~~Operations” ~~can~~included ~~find~~in ~~them~~our Annual Report. Each of these risk factors, either ~~see~~alone ~~“Where~~or ~~You~~taken ~~Can~~together, ~~Find~~could ~~More~~adversely ~~Information”~~affect our business, operating results and ~~“Incorporation~~financial ofcondition, ~~Certain~~as ~~Documents~~well Byas adversely ~~Reference~~affect the value of an investment in our common stock.” ~~Additional~~There may be additional risks that we do not presently ~~known~~know of or that we ~~presently~~currently believe ~~consider~~are ~~to be~~ immaterial that could ~~subsequently~~also ~~materially~~impair our business, operating results and financial position. If any of the events described ~~adversely~~below ~~affect~~were to occur, our business, financial condition, ability to access capital resources, results of operations, ~~business,~~ and future growth prospects could be materially and adversely affected and the market price of our common stock could decline. As a result, you could lose some or all of any investment that you may make in our common stock.

Risks Related to this Offering

You will experience immediate dilution in the net tangible book value per share of the common stock you purchase, and may experience additional dilution in the future.

The effective public offering price per share will be substantially higher than the net tangible book value per share of the outstanding shares of our common stock immediately after this offering. Based on an assumed combined public offering price of $0.6021 per share and accompanying Common Warrants, and our net tangible book value as of March 31, 2026, if you purchase our securities (assuming full exercise of any Pre-funded Warrants and 100% of the shares offered in this offering are sold) in this offering, you will pay more for your shares of common stock than the amounts paid by our existing shareholders for their shares of common stock and you will suffer immediate dilution of approximately $0.488 per share in net tangible book value. In addition, the shares of common stock issuable upon the exercise of the Common Warrants to be issued pursuant to the offering will further dilute the ownership interest of shareholders not participating in this offering and holders of outstanding warrants who have not exercised their warrants. As a result of this dilution, investors purchasing securities in this offering may receive significantly less than the full purchase price that they paid for the shares of common stock purchased in this offering in the event of a liquidation. To the extent shares of common stock are issued under outstanding convertible preferred stock, options and warrants at exercise prices lower than the public offering price of our shares of common stock in this offering, including the shares of common stock underlying the Pre-funded Warrants, holders will incur further dilution.

We have broad discretion in the use of the net proceeds we receive from this offering and may not use them effectively.

Our management will have broad discretion in the application of the net proceeds we receive in this offering, including for any of the purposes described in the section entitled “Use of Proceeds,” and you will not have the opportunity as part of your investment decision to assess whether our management is using the net proceeds appropriately. Because of the number and variability of factors that will determine our use of our net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business and cause the price of our common stock to decline. Pending their use, we may invest our net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders.

An active trading market for our shares may not be sustained.

Although our shares are listed on The Nasdaq Stock Market LLC, the market for our shares has demonstrated varying levels of trading activity. The current level of trading may not be sustained in the future. The lack of an active market for our shares may impair investors’ ability to sell their shares at the time they wish to sell them or at a price that they consider reasonable, may reduce the fair market value of their shares and may impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire additional intellectual property assets by using our shares as consideration.

This offering may cause the trading price of our common stock to decrease.

The number of shares of common stock underlying the securities we propose to issue and ultimately will issue if this offering is completed, may result in an immediate decrease in the market price of our common stock. This decrease may continue after the completion of this offering. We cannot predict the effect, if any, that the availability of shares for future sale represented by the Pre-funded Warrants or Common Warrants issued in connection with the offering will have on the market price of our common stock from time to time.

Future sales of substantial amounts of our common stock could adversely affect the market price of our common stock.

We may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. If additional capital is raised through the sale of equity or convertible debt securities, or perceptions that those sales could occur, the issuance of these securities could result in further dilution to investors purchasing our common stock in this offering or result in downward pressure on the price of our common stock, and our ability to raise capital in the future. We currently have an equity financing facility with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which we may sell up to $10 million in shares of common stock to Lincoln Park, all of which are covered by an effective registration statement that we have filed with the SEC. As of the date of this prospectus, we have issued and sold 48,848 shares to Lincoln Park and may further sell up to 638,651 additional shares to Lincoln Park, although such sales cannot commence until September 11, 2025. As of April 4, 2025 we had 6,199,965 outstanding shares of common stock. Any decline in the price of our common stock may encourage short sales, which could place further downward pressure on the price of our common stock and may impair our ability to raise additional capital through the sale of equity securities.

We are ~~have~~currently ~~effected~~listed ~~one~~on ~~for~~The ~~eight~~Nasdaq ~~and~~Capital aMarket. ~~one~~Failure to maintain our compliance with Nasdaq’s continued listing standards ~~for~~or ~~ten~~other ~~reverse~~requirements ~~stock~~could ~~splits~~result in ~~the~~our ~~last~~common ~~two~~stock ~~years~~being ~~and~~delisted wefrom ~~may~~Nasdaq, ~~not~~which becould ~~able~~adversely toaffect ~~cure~~our aliquidity ~~Nasdaq~~and ~~listing~~the trading ~~deficiency~~volume ifand market price of our common stock ~~price~~and ~~falls below~~decrease ~~$0.32~~or ~~per~~eliminate ~~share~~your investment.

~~Under Nasdaq rules, a reverse stock split taken~~Our ~~together~~common ~~with all other reverse~~ stock ~~splits~~is ~~that~~currently ~~are~~listed ~~effected~~on inthe aNasdaq ~~two~~Capital ~~year~~Market ~~period~~on ~~that~~Nasdaq isunder inthe ~~excess~~symbol of“TNON.” ~~one~~Nasdaq ~~for~~requires ~~two~~listed ~~hundred fifty (1:250)~~issuers ~~will~~to ~~not~~comply bewith ~~accepted~~certain bystandards ~~Nasdaq~~in asorder ~~a method~~ to ~~regain~~remain ~~compliance~~listed ~~with~~on ~~the~~its ~~Bid~~exchange. ~~Price~~We ~~Rule.~~must ~~Since~~meet ~~November~~certain 2,standards ~~2023,~~of wethe ~~have~~Nasdaq ~~affected~~Stock ~~two~~Market ~~reverse~~LLC ~~stock~~(“Nasdaq”) ~~splits~~including, ~~which~~but ~~collectively~~not ~~are~~limited ~~considered~~ to ~~have~~financial aand ~~ratio~~liquidity ~~of one for eighty (1:80). Therefore~~criteria, ~~until~~to ~~November~~maintain 3,the ~~2025,~~listing ~~Nasdaq will~~of ~~may~~our ~~not~~common ~~accept additional reverse~~ stock on ~~splits~~Nasdaq. ~~effected~~If bywe usviolate ~~with~~the amaintenance ~~ratio~~requirements ~~greater~~for ~~than~~continued ~~1:3.125~~listing asof aour ~~method~~common tostock, ~~regain~~our ~~compliance with~~common ~~the~~stock ~~Bid~~may ~~Price~~be ~~Rule~~delisted. ~~Accordingly~~In addition, ~~until~~our ~~November~~board 3,of ~~2025,~~directors ~~a reverse stock split acceptable to Nasdaq~~ may ~~not~~determine ~~cure~~that ~~noncompliance with~~ the ~~Bid~~cost ~~Price~~of ~~Rule~~maintaining if our ~~stock~~listing ~~was~~on ~~trading~~a atnational orsecurities ~~about~~exchange ~~$0.32~~outweighs ~~per~~the benefits ~~share.~~of If such anlisting. ~~event~~A ~~were~~delisting toof ~~occur,~~our ~~there~~common isstock nofrom ~~certainty~~Nasdaq ~~that~~for any ~~corporate~~ ~~action~~reason wemay ~~could~~materially ~~take~~impair orour ~~any~~stockholders’ ~~event~~ability to ~~would~~buy ~~occur~~and ~~that~~sell ~~would~~our ~~result~~common instock and could have an ~~increase~~adverse ineffect ~~our~~on ~~stock~~the market price ~~necessary~~of, ~~for~~and usthe toefficiency ~~regain compliance~~of ~~prior~~the ortrading ~~allow~~market for, our acommon ~~reverse~~ stock. ~~split~~In ~~with~~addition, athe ~~ratio~~delisting of ~~1:3.125~~our orcommon ~~less~~stock tocould ~~result~~significantly inimpair ~~compliance~~our ~~prior~~ability to araise ~~delisting of our common stock~~capital.

On February 25, 2026, we received a letter (the “Notification Letter”) from the Nasdaq Listing Qualifications Staff of Nasdaq stating that for the 30 consecutive business day period between January 9, 2026 and February 24, 2026, our common stock had not maintained a minimum closing bid price of $1.00 per share which is required for continued listing on Nasdaq. We were provided an initial period of 180 calendar days, or until August 24, 2026 (the “Compliance Period”), to regain compliance with the Bid Price Rule. To regain compliance, the closing bid price of our common stock must be at least $1.00 per share for a minimum of 10 consecutive business days during the Compliance Period.

If we do not regain compliance with the Bid Price Rule by August 24, 2026, we may be eligible for an additional 180-day period to regain compliance. To qualify, we would have to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the Bid Price Rule, and would need to provide written notice of its intention to cure the bid price deficiency during the second compliance period, by effecting a reverse stock split, if necessary. If we cannot regain compliance during the Compliance Period or any subsequently granted compliance period, our common stock will be subject to delisting. At that time, we may appeal the delisting determination to a Nasdaq hearings panel.

In addition, on May 21, 2026, we received a written notice from Nasdaq, notifying us that we are no longer in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires listed companies to maintain stockholders’ equity of at least $2,500,000 (“Stockholders’ Equity Rule”). In our Quarterly Report on Form 10-Q for the period ended March 31, 2026, we reported stockholders’ equity of $1,895,000. We do not currently meet the alternative compliance standards relating to the market value of listed securities or net income from continuing operations. Under Nasdaq rules, we have 45 calendar days, or until July 6, 2026, to submit a plan or regain compliance. If it is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the notice for the Company to regain compliance.

The notices from Nasdaq have no immediate effect on the listing of our common stock, which will continue to be listed on Nasdaq under the symbol “TNON.” We are currently evaluating our options for regaining compliance with the Bid Price Rule. We are also presently evaluating various courses of action to regain compliance if as a result of this offering Nasdaq does not consider us in compliance with the Stockholders’ Equity Rule and would intend to timely submit a plan to Nasdaq to regain compliance with the Stockholders’ Equity Rule. However, in such cases there can be no assurance that our plan would be accepted or that if it is, we would be able to regain compliance and maintain our listing on The Nasdaq Capital Market. If we fail to regain compliance with the Stockholders’ Equity Rule as a result of this offering or fail to submit a plan to regain compliance, or our plan is not accepted, or if Nasdaq grants an extension but we do not regain compliance within the extension period, Nasdaq will provide notice that our securities will become subject to delisting. In such event, Nasdaq rules would permit the Company to appeal the decision to reject the Company’s proposed compliance plan or any delisting determination to a Nasdaq Hearings Panel. The hearing request would stay any suspension or delisting action pending the conclusion of the hearing process and the expiration of any additional extension period granted by the panel following the hearing.

There is no assurance that we will regain compliance with the Bid Price Rule, the Stockholders’ Equity Rule, or maintain compliance with any of the other Nasdaq continued listing requirements.

Additionally, in January 2026, Nasdaq proposed a rule change that would require companies listed on the Nasdaq Global and Capital Markets to maintain a minimum market value of listed securities (“MVLS”) of at least $5 million. If adopted, this requirement would represent an additional continued listing standard applicable to our common stock. Under the proposed rule, if a company’s MVLS falls below $5 million for 30 consecutive business days, Nasdaq would immediately suspend trading and delist the company’s securities, with no compliance or cure period. Unlike some other Nasdaq listing deficiencies, the proposed rule would not provide an opportunity to regain compliance prior to suspension, and a hearing request would not stay the suspension of trading.

The market value of our common stock may fluctuate significantly due to a number of factors, many of which are outside of our control, including market conditions, investor sentiment toward small-cap companies, our operating performance, and general economic conditions. As a result, we may be unable to maintain the required MVLS threshold at all times. If this proposed rule is approved and adopted, any sustained decline in our MVLS below $5 million could result in the immediate suspension and delisting of our common stock from Nasdaq.

A delisting of our common stock and our inability to list on another national securities market could negatively impact us by: (i) reducing the liquidity and market price of our common stock; (ii) reducing the number of investors willing to hold or acquire our common stock, which could negatively impact our ability to raise equity financing; (iii) limiting our ability to use certain registration statements to offer and sell freely tradable securities, thereby limiting our ability to access the public capital markets; and (iv) impairing our ability to provide equity incentives to our employees.

710

~~Purchasers~~Any delisting determination by Nasdaq could seriously decrease or eliminate the value of an investment in our common stock ~~may~~and ~~incur~~other ~~immediate~~securities linked ~~dilution~~to our common stock. While a listing on an over-the-counter exchange could maintain some degree of a market in our common stock, we could face substantial material adverse consequences, including, but not limited to, the following:

~~Purchasers~~● oflimited ~~shares~~availability offor ~~common~~market ~~stock~~quotations infor ~~this~~our ~~offering may experience immediate and substantial dilution if the purchase price of the~~ common stock paid by such purchasers is higher than the net tangible book value per share of the outstanding common stock. In addition, purchasers will experience dilution, which may be substantial, when we issue additional shares of common stock that we are permitted or required to issue under options, our stock equity incentive plans or other employee or director compensation plans.;

~~Our~~● ~~Series~~reduced Aliquidity ~~Preferred~~with ~~Stock~~respect to and ~~Series B~~decreased ~~Preferred~~trading ~~Stock~~prices ~~rank~~of ~~senior to~~ our common stock.;

~~Our~~● ~~Series~~a Adetermination ~~Preferred~~that ~~Stock~~shares ~~and Series B Preferred Stock rank, with respect to rights on the distribution~~ of ~~assets~~our oncommon ~~any~~stock ~~voluntary~~are or“penny ~~involuntary~~stock” ~~liquidation,~~under ~~dissolution~~SEC ~~or winding up of the affairs of our company~~rules, ~~and~~subjecting ~~redemption~~brokers ~~rights,~~trading ~~senior to~~ our common stock ~~and~~to ~~each~~more ~~other~~stringent ~~class~~rules oron ~~series~~disclosure ofand ~~securities now existing or hereafter authorized classified or reclassified,~~ the ~~terms~~class of ~~which~~investors ~~do not expressly provide that such class or series ranks on a parity basis with or senior~~ to ~~the~~which ~~Series A Preferred Stock and Series B Preferred Stock as to rights on~~ the ~~distribution~~broker ofmay ~~assets~~sell ~~on any voluntary or involuntary liquidation, dissolution or winding up of~~ the ~~affairs~~common ~~of our company, and redemption rights.~~stock;

~~Conversion~~● oflimited ~~Series~~news Aand ~~Preferred~~analyst ~~Stock, the~~coverage ~~Series~~for Bour ~~Preferred Stock or the exercise of the Tradeable Warrants~~Company, ~~Note~~in ~~Warrants,~~part ~~the~~due ~~Series~~to ~~A Warrants,~~ the ~~Series~~“penny Bstock” ~~Warrants or the Warrants may cause significant dilution to our stockholders.~~rules;

As● ofdecreased ~~April~~ability 4,to ~~2025,~~issue weadditional ~~have~~securities ~~issued~~or ~~256,968~~obtain ~~shares of~~additional ~~Series~~financing Ain Preferred Stock, which are convertible into 788,587 shares of common stock; 86,454 shares of Series B Preferred Stock, which are convertible into 108,074 shares of common stock; tradeable warrants with 250,000 underlying shares of common stock (the ~~“Tradeable Warrants”)~~future; warrants issued with convertible notes with 5,625 underlying shares of common stock (the “Note Warrants”); Series A Warrants with 51,934 underlying shares of common stock (the “Series A Warrants”), Series B Warrants with 16,214 underlying shares of common stock (the “Series B Warrants”) and the Warrants with 5,673,550 underlying shares of common stock. The issuance of shares of common stock upon the conversion of such shares of preferred stock or exercise of any of such warrants would dilute the percentage ownership interest of holders of our common stock, dilute the book value per share of our common stock, and increase the number of our publicly traded shares, which could further depress the market price of our common stock.

In● ~~addition,~~potential ~~the~~breaches ~~Series~~under Aor ~~Warrants,~~terminations ~~Series B Warrants and the Note Warrants contain weighted average anti-dilution provisions which, subject to limited exceptions, would increase the number~~ of ~~shares~~our ~~issuable~~agreements ~~upon~~with ~~exercise~~current ~~of such securities (by reducing the exercise price) in the event that we in the future issue common stock,~~ or ~~securities~~prospective ~~convertible~~large ~~into or exercisable to purchase common stock~~stockholders, atstrategic ainvestors ~~price~~and ~~per share lower than the exercise price then in effect~~banks.

8The perception among investors that we are at heightened risk of delisting could also negatively affect the market price of our securities and trading volume of our common stock.

There is no public market for the Common Warrants or Pre-funded Warrants being offered by us in this offering.

There is no established public trading market for the Common Warrants or the Pre-funded Warrants, and we do not expect a market to develop. In addition, we do not intend to apply to list the Common Warrants or the Pre-funded Warrants on any national securities exchange or other nationally recognized trading system. Consequently, there is no public trading market for the warrants, and we do not expect a market to develop. Accordingly, investors may find it difficult to dispose of, or to obtain accurate quotations as to the market value of, the warrants. This lack of a trading market could result in investors being unable to liquidate their investment in the warrants or to sell them at a price that reflects their value. The absence of a public market for these securities could also reduce the liquidity and market price of our common stock to which these warrants are exercisable. Investors should be prepared to bear the risk of investment in the Common Warrants and the Pre-funded Warrants indefinitely.

The Common Warrants are speculative in nature.

The Common Warrants will be exercisable for five years from the date of initial exercise at an exercise price of $[*] per share (at an exercise price equal to 100% of the assumed combined public offering price per share of our common stock and accompanying Common Warrants that is based on the closing price of the Company’s common stock on Nasdaq on June 17, 2026). There can be no assurance that the market price of the common stock will ever equal or exceed the exercise price of the Common Warrants. In the event that our common stock price does not exceed the exercise price of the Common Warrants during the period when the Common Warrants are exercisable, a holder of the Common Warrants may be unable to profit from exercising such Common Warrants before they expire.

Except as otherwise provided in the Common Warrants and Pre-funded Warrants, holders of Common Warrants and Pre-funded Warrants purchased in this offering will have no rights as stockholders until such holders exercise their Common Warrants or Pre-funded Warrants and acquire our common stock.

Holders of the Common Warrants and the Pre-funded Warrants will not have the same voting rights as those associated with our common stock and may have no voting rights with respect to the shares underlying the warrants until such shares are acquired upon exercise of the warrants. As a result, if such holders do not exercise their warrants, they will not have any influence over matters requiring stockholder approval during the period they hold the Common Warrants and Pre-funded Warrants, as applicable.

Since we do not expect to pay any cash dividends for the foreseeable future, investors may be forced to sell their stock in order to obtain a return on their investment.

We do not anticipate declaring or paying in the foreseeable future any cash dividends on our capital stock. Instead, we plan to retain any earnings to finance our operations and growth plans discussed elsewhere or incorporated by reference in this prospectus. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any return on their investment. As a result, investors seeking cash dividends should not purchase our common stock.

Adjustments to the terms of Pre-funded Warrants.

The terms of the Pre-funded Warrants, including the exercise price and the number of shares of common stock issuable upon exercise, may be adjusted in certain circumstances, including in the event of stock dividends, stock splits, and similar transactions. While adjustments are generally intended to prevent dilution for holders of Pre-funded Warrants, there is no assurance that such adjustments will fully protect the value of the Pre-funded Warrants.

The Common Warrants and the Pre-funded Warrants have beneficial ownership limitations.

An investment in our Common Warrants and Pre-funded Warrants involves a significant risk due to the 4.99% (or 9.99% if the investor so elects) beneficial ownership limitation. The terms of the Common Warrants and the Pre-funded Warrants prohibit any single holder from exercising the warrants if such exercise would result in the holder beneficially owning more than 4.99% (or 9.99% if the investor so elects) of our outstanding common stock immediately after the exercise, as elected by the holder at the time of issuance of the warrants. This limitation may also hinder the holder’s ability to sell or exercise the Common Warrants or the Pre-funded Warrants when it may be most advantageous to do so, which could affect the value of their investment.

We will not receive any meaningful amount of additional funds upon the exercise of the Pre-funded Warrants.

Each Pre-funded Warrant will be exercisable and will have no expiration date and by means of payment of the nominal cash purchase price upon exercise. Accordingly, we will not receive any or any meaningful additional funds upon the exercise of the Pre-funded Warrant.

We may amend the terms of the warrants in a way that may be adverse to holders with the approval by the holders of a majority of the then outstanding warrants.

Our warrant agent agreement with Vstock Transfer, LLC (“Warrant Agent Agreement”) provides that the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision. All other modifications or amendments, including any amendment to increase the exercise price of the warrants or shorten the exercise period of the warrants, shall require the written consent of the registered holders of a majority of the then outstanding warrants which may be contrary to your interests.

Our Warrant Agent Agreement designate the courts of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders to obtain a favorable judicial forum for disputes with us.

Our Warrant Agent Agreement provides that, subject to applicable law, (i) any action, proceeding or claim against us arising out of or relating in any way to the Warrant Agent Agreement, including under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such courts represent an inconvenient forum.

Notwithstanding the foregoing, these provisions of the Warrant Agent Agreement do not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and to have consented to the forum provisions in our Warrant Agent Agreement.

If any action, the subject matter of which is within the scope of the forum provisions of the Warrant Agent Agreement, is filed in a court other than courts of the State of New York or the United States District Court for the Southern District of New York (a “foreign action”) in the name of any holder of our warrants, such holder shall be deemed to have consented to: (x) the personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such court to enforce the forum provisions (an “enforcement action”), and (y) having service of process made upon such warrant holder in any such enforcement action by service upon such warrant holder’s counsel in the foreign action as an agent for such warrant holder.

This choice-of-forum provision may limit a warrant holder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us, which may discourage such lawsuits. Alternatively, if a court were to find this provision of our Warrant Agent Agreement inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result in a diversion of the time and resources of our management and Board.

IN ADDITION TO THE ABOVE RISKS, BUSINESSES ARE OFTEN SUBJECT TO RISKS NOT FORESEEN OR FULLY APPRECIATED BY MANAGEMENT. IN REVIEWING THIS FILING, POTENTIAL INVESTORS SHOULD KEEP IN MIND THAT OTHER POSSIBLE RISKS MAY ADVERSELY IMPACT THE COMPANY’S BUSINESS OPERATIONS AND THE VALUE OF THE COMPANY’S SECURITIES.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This prospectus contains “forward-looking statements.” Forward-looking statements reflect the current view about future events. When used in this prospectus, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this prospectus relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:

●

Our ability to effectively operate our business segments;

●

Our ability to manage our research, development, expansion, growth, and operating expenses;

●

Our ability to evaluate and measure our business, prospects, and performance metrics;

●

Our ability to compete, directly and indirectly, and succeed in the highly competitive medical devices industry;

●

Our ability to respond and adapt to changes in technology and customer behavior;

●

Our ability to protect our intellectual property and to develop, maintain and enhance a strong brand; and

● Other factors (including the risks contained in our most recent Annual Report on Form 10-K and in the ~~section~~other ofdocuments ~~this~~that ~~prospectus~~we ~~entitled~~include ~~“Risk~~or ~~Factors”~~incorporate by reference into this prospectus) relating to our industry, our operations and results of operations, including risks related to FDA regulatory requirements, potential changes in the regulatory environment for medical devices, our ability to maintain regulatory clearances and approvals for our products, and our ability to obtain any additional regulatory clearances or approvals that may be required.

Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

THE WARRANT INDUCEMENT

On March 11, 2025, we entered into the Inducement Letter with the Selling Stockholder that had previously purchased warrants (the “Old Warrants”) from the Company on September 16, 2024. Pursuant to the Inducement Letter, the Selling Stockholder agreed to exercise for cash the Old Warrants to purchase an aggregate of 2,445,700 shares of common stock, at the exercise price of $1.25 per share in consideration for our agreement to issue (i) the Series C-1 Warrants to purchase up to an aggregate of 2,445,700 shares of Common Stock at an exercise price of $1.25 per share, which are exercisable for five years after the effective date of this registration statement and (ii) the Series C-2 Warrants to purchase up to an aggregate of 1,222,850 shares of Common Stock at an exercise price of $1.25 per share, which are exercisable for three years after the effective date of this registration statement. The transactions referred to above are collectively referred to as the “Warrant Inducement.” The offer and resale of the shares of common stock underlying the Old Warrants was registered pursuant to our registration statement on Form S-1 (File No. 333-283521).

The Company entered into a financial advisory agreement (the “Financial Advisory Agreement”) with A.G.P./Alliance Global Partners (“AGP”) to act as its financial advisor in connection with the transactions summarized above. Pursuant to the Financial Advisory Agreement, the Company will pay AGP a cash fee of 7% of the aggregate gross proceeds from the exercise of the Old Warrants. Additionally, the Company agreed to reimburse AGP for its documented accountable legal expenses up to $40,000.

In connection with the Warrant Inducement, we received aggregate gross proceeds of approximately $3 million (the “Warrant Inducement”). The Company intends to use the net proceeds for working capital and general corporate purposes.

Pursuant to the Inducement Letter, we agreed to file the registration statement related to this prospectus within thirty (30) calendar days following the date of the Inducement Letter and to use commercially reasonable efforts to cause such registration statement to become effective within sixty (60) calendar days from the date of the Inducement Letter (or within 90 calendar days if such registration statement is reviewed by the SEC). Pursuant to the Inducement Letter, the Company agreed not to issue, enter into any agreement to issue or announce the issuance or proposed issuance of any Common Stock or Common Stock equivalents or file any registration statement or any amendment or supplement to any existing registration statement, subject to certain exceptions, for a period of sixty (60) calendar days after the effectiveness of the registration statement related to this offering. Furthermore, the Company is also prohibited from entering into any agreement to issue Common Stock or Common Stock equivalents involving a variable rate transaction, subject to certain exceptions, for a six-month period commencing on March 12, 2025.

THE CONCURRENT PRIVATE PLACEMENTS

On March 25, 2025, we entered into the Series D Purchase Agreement with the Selling Stockholder, pursuant to which we issued to the Selling Stockholder (i) in a registered direct offering (x) 615,000 shares of our common stock at a purchase price of $2.00 per share and (y) pre-funded warrants to purchase up to 118,500 shares of Common Stock at $1.9999 per pre-funded warrant and (ii) in a concurrent private placement, the Series D Warrants. The Series D Warrants have five year terms and are exercisable at $2.00 per share. The offerings described above closed on March 26, 2025 and the Company received gross of approximately $1.46 million. The securities offered and sold under the registered direct offering were offered by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-271648), which was declared effective by the SEC on May 17, 2023 (as amended from time to time, the “S-3 Registration Statement”). The Series D Warrants were issued in a concurrent private placement pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares underlying the Series D Warrants are part of the Selling Stockholder Shares being registered pursuant to the registration statement related to this prospectus.

On March 25, 2025, we also entered into the Series E Purchase Agreement with the Selling Stockholder, pursuant to which we issued to the Selling Stockholder (i) in a registered direct offering (x) 615,000 shares of our common stock at a purchase price of $2.00 per share and (y) pre-funded warrants to purchase up to 656,500 shares of Common Stock at $1.9999 per pre-funded warrant and (ii) in a concurrent private placement, the Series E Warrants. The Series E Warrants have five year terms and are exercisable at $2.00 per share. The offerings described in this paragraph closed on March 27, 2025, and the Company received gross of approximately $2.54 million. The securities offered and sold under the registered direct offering were offered by the Company pursuant to the S-3 Registration Statement. The Series D Warrants were issued in a concurrent private placement pursuant to the exemption from registration provided in Section 4(a)(2) under the Securities Act and Rule 506(b) promulgated thereunder. The shares underlying the Series E Warrants are part of the Selling Stockholder Shares being registered pursuant to the registration statement related to this prospectus.

AGP acted as the exclusive placement agent (the “Placement Agent”) on a “reasonable best efforts” basis, in connection with both registered direct offering and concurrent private placements referred to above pursuant to two placement agency agreements, each dated March 25, 2025 (the “Placement Agency Agreements”), and each by and between the Company and the Placement Agent. The placement Agent received pursuant to each Placement Agency Agreement, a cash fee of 7.0% of the aggregate gross proceeds paid to the Company for the securities sold in the respective offerings, pursuant to the Placement Agency Agreement with respect to the Series D Warrants, $10,000 in non-accountable expenses and reimbursement of certain out-of-pocket expenses up to a maximum of $50,000 and pursuant the Placement Agency Agreement with respect to the Series E Warrants, reimbursement of certain out-of-pocket expenses up to a maximum of $30,000.

USE OF PROCEEDS

The Selling Stockholder will receive all of the proceeds of the sale of the Selling Stockholder Shares offered from time to time pursuant to this prospectus. Accordingly, we will not receive any proceeds from the sale of Selling Stockholder Shares that may be sold from time to time pursuant to this prospectus; however, we will receive proceeds from the cash exercise of the Warrants. We currently intend to use these net proceeds for working capital and general corporate purposes.

We will bear the out-of-pocket costs, expenses and fees incurred in connection with the registration of the Selling Stockholder Shares to be sold by the Selling Stockholder pursuant to this prospectus. Other than registration expenses, the Selling Stockholder will bear any underwriting discounts, commissions, placement agent fees or other similar expenses payable with respect to sales of Selling Stockholder Shares.

SELLING STOCKHOLDER

The Selling Stockholder Shares offered by the Selling Stockholder are those issuable to the Selling Stockholder upon exercise of the Warrants. For additional information regarding the issuance of the Series C Warrants, see “The Warrant Inducement” above. We are registering the Selling Stockholder Shares in order to permit the Selling Stockholder to offer the Selling Stockholder Shares for resale from time to time.

Except for as described in this prospectus, the Selling Stockholder has not had any material relationship with us within the past three years.

The table below lists the Selling Stockholder and provides information regarding its beneficial ownership of shares of our common stock. The second column lists the number of shares of common stock beneficially owned by the Selling Stockholder based on its ownership of shares of common stock and warrants, as of April 4, 2025, assuming exercise of the warrants held by the Selling Stockholder on that date, without regard to any limitations on exercises. The third column lists the maximum number of shares of common stock being offered by this prospectus by the Selling Stockholder, also without regard to any limitations on exercises.

In accordance with the terms of the Inducement Letter, this prospectus generally covers the resale of the maximum number of shares of common stock issuable upon exercise of the Warrants, determined as if the outstanding Series C Warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially filed with the SEC, without regard to any limitations on the exercise of the Warrants. The fourth and fifth columns assume the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus.

Under the terms of the Series C Warrants, the Selling Stockholder may not exercise the Common Warrants to the extent such exercise would cause such Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares of Common Stock that would exceed 4.99%, of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable upon exercise of such warrants which have not been exercised. The number of shares in the second and third columns do not reflect this limitation. The Selling Stockholder may sell all, some or none of their shares in this offering. See “Plan of Distribution.”

Name of Selling Stockholder		Number of Shares of Common Stock Beneficially Owned Prior to Offering(1)				Maximum Number of Shares of Common Stock to be Sold in this Offering(2)				Number of Shares of Common Stock Beneficially Owned After Offering				Percentage of Shares Beneficially Owned after Offering(2)
Armistice Capital, LLC(3)			5,695,800	(1)			5,673,550				22,250				*	%

* Less than 1%

(1)	Consists of 5,673,550 shares of our common stock underlying the Warrants, and 22,250 shares underlying warrants issued to the Selling Stockholder in June 2023 in a public offering.
(2)	The Warrants are subject to a beneficial ownership limitation of 4.99%, which in each case restricts the Selling Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of Common Stock in excess of the beneficial ownership limitation. The number of shares set forth in the above table does not reflect the application of this limitation.
(3)	The securities are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the “Master Fund”), and may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (“Armistice Capital”), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The warrants are subject to a beneficial ownership limitation of 4.99%, which such limitation restricts the Selling Stockholder from exercising that portion of the warrants that would result in the Selling Stockholder and its affiliates owning, after exercise, a number of shares of common stock in excess of the beneficial ownership limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York, NY 10022.

PLAN OF DISTRIBUTION

We are registering the Selling Stockholder Shares issuable to the Selling Stockholder upon the exercise of the Series C Warrants to permit the resale of such shares of common stock by such Selling Stockholder from time to time pursuant to this prospectus. We will not receive any of the proceeds from the sale by the Selling Stockholder of the Selling Stockholder Shares. We will bear all fees and expenses incident to our obligation to register such shares of common stock.

The Selling Stockholder of the shares of the securities and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of the securities covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. The Selling Stockholder may use any one or more of the following methods when selling securities:

● ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; ● block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; ● purchases by a broker-dealer as principal and resale by the broker-dealer for its account; ● an exchange distribution in accordance with the rules of the applicable exchange; ● privately negotiated transactions; ● settlement of short sales; ● in transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security; ● through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; ● a combination of any such methods of sale; or ● any other method permitted pursuant to applicable law.

The Selling Stockholder may also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus.

Broker-dealers engaged by the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in compliance with FINRA Rule 2121.

~~In connection with the sale of the securities~~USE orOF interests therein, the Selling Stockholder may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholder may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholder may also enter into option or other transactions with broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).PROCEEDS

~~The~~We estimate ~~Selling~~that ~~Stockholder~~the ~~and~~net ~~any~~proceeds ~~broker-dealers or~~to ~~agents~~us ~~that~~from ~~are~~this ~~involved~~offering infrom ~~selling~~ the ~~securities~~sale ~~may~~of beshares ~~deemed~~of tothe beCompany’s ~~“underwriters”~~common ~~within~~stock ~~the~~based ~~meaning~~on of the ~~Securities~~assumed ~~Act~~combined inpublic ~~connection~~offering ~~with~~price ~~such~~of ~~sales~~$0.6021 Inper ~~such~~share ~~event,~~of ~~any~~common ~~commissions~~stock, ~~received~~and byaccompanying ~~such~~Common ~~broker-dealers~~Warrants, orwhich ~~agents~~represents ~~and any profit on~~ the ~~resale~~closing price of ~~the~~our ~~securities~~common ~~purchased~~stock byon itJune ~~may~~17, be2026 ~~deemed~~and toassuming beno ~~underwriting~~sales ~~commissions~~of orPre-funded ~~discounts~~Warrants, ~~under~~no ~~the~~exercise ~~Securities~~of ~~Act.~~Common ~~The~~Warrants, ~~Selling~~and ~~Stockholder has~~no ~~informed~~exercise ~~the~~of overallotment ~~Company~~option ~~that~~will itbe ~~does~~approximately ~~not~~$2,972,500, ~~have~~after ~~any~~deducting ~~written~~the orunderwriting ~~oral~~discounts ~~agreement~~and orcommissions ~~understanding,~~and ~~directly~~estimated ~~or indirectly, with any person~~offering ~~to distribute the securities~~expenses.

~~The~~We ~~Company~~intend isto ~~required~~use the net proceeds of this offering to ~~pay~~repay ~~certain~~a ~~fees~~portion of our convertible notes payable and ~~expenses~~ ~~incurred~~accrued byinterest ~~the~~thereon ~~Company~~and ~~incident~~for toexpansion of the ~~registration~~commercial footprint of ~~the~~our product ~~securities.~~portfolio ~~The~~including ~~Company~~training ~~has~~clinicians ~~agreed~~on toour ~~indemnify~~current ~~the~~procedures, ~~Selling~~hiring ~~Stockholder against~~additional ~~certain~~direct ~~losses~~sales reps, ~~claims~~expansion of our external distribution network, ~~damages~~continuing clinical research studies to support reimbursement and ~~liabilities~~coverage efforts, funding research and development including ~~liabilities~~upcoming ~~under~~future ~~the~~launches, ~~Securities~~and ~~Act~~increases to inventory and instrumentation capacities, as well as other marketing activities, working capital and general corporate purposes.

We will ~~have~~retain ~~agreed~~broad todiscretion ~~keep~~in ~~this~~the ~~prospectus~~allocation ~~effective until all~~ of the ~~securities~~net ~~have~~proceeds ~~been~~from ~~sold pursuant to~~ this ~~prospectus~~offering orand ~~Rule~~could ~~144~~utilize ~~under~~ the ~~Securities~~proceeds ~~Act or any other rule of similar effect. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition,~~ in ~~certain~~ways ~~states,~~that ~~the resale securities covered hereby may~~ do not benecessarily ~~sold~~improve ~~unless~~our ~~they~~results ~~have~~of ~~been~~operations ~~registered~~ or ~~qualified for~~enhance ~~sale in~~ the ~~applicable~~value ~~state~~of orour ancommon ~~exemption from the registration or qualification requirement is available and is complied with~~stock.

~~Under applicable rules and regulations under the~~The ~~Exchange~~following ~~Act,~~table ~~any~~sets ~~person~~forth ~~engaged in~~ the ~~distribution~~uses of the resale securities may not simultaneously engage in market making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distributionproceeds. In addition, the Selling Stockholder will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling Stockholder or any other person. We will make copies of this prospectus available to the Selling Stockholder and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule 172 under the Securities Act).

Description	Amount
Gross proceeds	$	3,500,000
Underwriting discount	$	227,500
Offering expenses	$	300,000
Net proceeds	$	2,972,500
Convertible note repayment	$	445,875
Expansion of the commercial footprint of our product portfolio including training clinicians on our current procedures	$	250,000
Hiring additional direct sales reps, expansion of our external distribution network	$	500,000
Continuing clinical research studies to support reimbursement and coverage efforts, funding research and development including upcoming future launches, and increases to inventory and instrumentation capacities and other marketing activities	$	1,276,625
Working capital and general corporate purposes	$	500,000
Total	$	2,972,500

The foregoing information is an estimate based on our current business plan. We may find it necessary or advisable to re-allocate portions of the net proceeds reserved for one category to another, and we will have broad discretion in doing so. Pending these uses, we intend to invest the net proceeds of this offering in a money market or other interest-bearing account. The amounts and timing of our actual expenditures will depend upon numerous factors, including our sales and marketing and commercialization efforts, demand for our products, our operating costs and the other factors described under “Risk Factors” in this prospectus, in our most recent Annual Report on Form 10-K and in the other documents that we include or incorporate by reference into this prospectus. Accordingly, our management will have flexibility in applying the net proceeds from this offering. An investor will not have the opportunity to evaluate the economic, financial or other information on which we base our decisions on how to use the proceeds.

DILUTION

If you invest in our securities in this offering, your ownership interest will be diluted immediately to the extent of the difference between the public offering price paid by the purchasers of the shares of common stock (or Pre-funded Warrants) and accompanying Common Warrants sold in this offering and the pro forma as adjusted net tangible book value per share of common stock after this offering.

Net tangible book value per share is determined by dividing our total tangible assets less total liabilities by the number of outstanding shares of our common stock. As of March 31, 2026, we had a net tangible book value of approximately $(982,000) or $(0.087) per share of common stock based upon 11,296,378 shares of common stock outstanding as of that date (exclusive of 276,228 shares of restricted unvested common stock).

After giving effect to the issuance, subsequent to March 31, 2026, of 276,228 shares of common stock to SiVantage, Inc., pursuant to the Asset Purchase Agreement, dated August 1, 2025, by and between the Company and SiVantage, Inc, our pro forma net tangible book value as of March 31, 2026 was approximately $(982) or $(0.085) per share of common stock, based upon 11,572,606 shares of common stock outstanding as of March 31, 2026. Pro forma net tangible book value represents net tangible book value adjusted to take into account issuances subsequent to March 31, 2026.

After giving effect to the sale of shares of common stock and accompanying Common Warrants in this offering at an assumed offering price of $0.6021 per share and accompanying Common Warrants, which was the closing price of our common stock as reported on the Nasdaq Capital Market on June 17, 2026, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, and assuming full exercise of any Pre-funded Warrants in this offering on the closing date, no exercise of the overallotment option, no exercise of the Common Warrants or Underwriter Warrants being offered in this offering, that no value is attributed to such warrants and that such warrants are classified as and accounted for as equity, our as adjusted pro forma net tangible book value would have been $0.114 per share. This represents an immediate increase in pro forma net tangible book value of $0.199 per share to existing stockholders and an immediate dilution in net tangible book value of $0.488 per share to investors purchasing securities in this offering at the assumed offering price. Dilution represents the difference between the amount per share paid by purchasers in this offering and the as adjusted pro forma net tangible book value per share of common stock after the offering.

The following table illustrates the dilution on a per share basis:

Assumed public offering price per share				$	0.6021
Historical net tangible book value per share as of March 31, 2026	$	(0.087	)
Pro forma net tangible book value per share	$	(0.085	)
Increase in pro forma net tangible book value per share attributable to this offering	$	0.199
Pro forma as adjusted net tangible book value per share after this offering				$	0.114
Dilution in net tangible book value per share to new investors in this offering				$	0.488

Each $0.10 increase (decrease) in the assumed public offering price of $0.6021 per share of common stock and accompanying Common Warrants would increase (decrease) the as adjusted pro forma net tangible book value by $0.031 per share of common stock and the dilution to new investors by $0.069 per share, after deducting the estimated underwriter discount and estimated offering expenses payable by us.

We may also increase or decrease the number of shares we are offering. An increase of 100,000 shares in the number of shares of common stock offered by us would increase our as adjusted pro forma net tangible book value by approximately $56,000, or approximately $0.003 per share of common stock, and decrease the dilution per share to investors in this offering by approximately $0.003 per share, assuming that the number of shares of common stock and accompanying Common Warrants offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting the estimated underwriter discount and estimated offering expenses payable by us. Similarly, a decrease of 100,000 shares in the number of shares of common stock offered by us would decrease our as adjusted pro forma net tangible book value by approximately $56,000, or approximately $0.003 per share, and increase the dilution per share to investors in this offering by approximately $0.003 per share, assuming the assumed combined offering price of $0.6021 per share of common stock and accompanying Common Warrant remains the same and after deducting the estimated underwriter discount and estimated offering expenses payable by us. The information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this offering as determined between us and the underwriter at pricing.

The above discussion and table are based on 11,296,378 shares of our common stock outstanding as of March 31, 2026 (exclusive of 276,228 shares of restricted unvested common stock), and excludes as of such date:

●

8,173,914 shares of common stock issuable upon the exercise of outstanding warrants with a weighted average exercise price equal to $2.11 per share;

●

17,697 shares of common stock issuable upon the exercise of outstanding stock options, with a weighted average exercise price equal to $13.12 per share;

●

536,192 shares of common stock issuable upon the vesting of RSUs; and

●

720,341 shares of common stock reserved for future issuance under Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended.

DESCRIPTION OF SECURITIES WE ARE OFFERING

Common Stock

The holders of our common stock are entitled to the following rights:

Voting Rights. Each share of our common stock entitles its holder to one vote per share on all matters to be voted or consented upon by the stockholders. Holders of our common stock are not entitled to cumulative voting rights with respect to the election of directors.

Election of Directors. The holders of our common stock, voting as a separate class, shall be entitled to elect one member of our Board.

Dividend Rights. Subject to limitations under Delaware law and preferences that may apply to any shares of preferred stock that we may decide to issue in the future, holders of our common stock are entitled to receive ratably such dividends or other distributions, if any, as may be declared by our Board out of funds legally available therefor.

Liquidation Rights. In the event of the liquidation, dissolution or winding up of our business, the holders of our common stock are entitled to share ratably in the assets available for distribution after the payment of all of our debts and other liabilities, subject to the prior rights of the holders of our preferred stock.

Other Matters. The holders of our common stock have no subscription, redemption or conversion privileges. Our common stock does not entitle its holders to preemptive rights. All of the outstanding shares of our common stock are fully paid and non-assessable. The rights, preferences and privileges of the holders of our common stock are subject to the rights of the holders of shares of any series of preferred stock which we may issue in the future.

Warrants

Pre-funded Warrants to be issued in this Offering

The following summary of certain terms and conditions of the Pre-funded Warrants is not complete and is subject to, and qualified in its entirety by, the provisions of Pre-funded Warrant, the form of which is filed as an exhibit to the registration statement of which this prospectus forms a part. Prospective investors should carefully review the terms and provisions of the form of Pre-funded Warrant for a complete description of the terms and conditions of the Pre-funded Warrants.

General

The term “pre-funded” refers to the fact that the purchase price of the Pre-funded Warrants in this offering includes almost the entire exercise price that will be paid under the Pre-funded Warrants, except for a nominal remaining exercise price of $0.0001. The purpose of the Pre-funded Warrants is to enable investors that may have restrictions on their ability to beneficially own more than 4.99% (or, at the election of the holder, 9.99%) of our outstanding common stock following the consummation of this offering the opportunity to invest capital into the Company without triggering their ownership restrictions, by receiving Pre-funded Warrants in lieu of shares of our common stock which would result in such ownership of more than 4.99% (or, at the election of the holder, 9.99%), and receiving the ability to exercise their option to purchase the shares underlying the Pre-funded Warrants at a nominal price at a later date.

Form

The Pre-funded Warrants will be issued as individual warrant agreements to the investors. You should review the form of Pre-funded Warrant, filed as an exhibit to the registration statement of which this prospectus forms a part, for a complete description of the terms and conditions applicable to the Pre-funded Warrants.

Exercisability

The Pre-funded Warrants are exercisable at any time after their original issuance. The Pre-funded Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full in immediately available funds for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise as described below). A holder (together with its affiliates) may not exercise any portion of the Pre-funded Warrant to the extent that the holder would own more than 4.99% (or, at the election of the holder, 9.99%) of the outstanding common stock immediately after exercise, except that upon at least 61 days’ prior notice from the holder to us, the holder may increase the amount of ownership of outstanding stock after exercising the holder’s Pre-funded Warrants up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Pre-funded Warrants.

Duration and Exercise Price

The exercise price per whole share of our common stock purchasable upon the exercise of the Pre-funded Warrants is $0.0001 per share of common stock. The Pre-funded Warrants will be immediately exercisable and may be exercised at any time until the Pre-funded Warrants are exercised in full.

Cashless Exercise

If, at any time after the issuance of the Pre-funded Warrants, the holder exercises its Pre-funded Warrants and a registration statement registering the issuance of the shares of common stock underlying the Pre-funded Warrants under the Securities Act is not then effective or available (or a prospectus is not available for the resale of shares of common stock underlying the Pre-funded Warrants), then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder shall instead receive upon such exercise (either in whole or in part) only the net number of shares of common stock determined according to a formula set forth in the Pre-funded Warrants. Notwithstanding anything to the contrary, in the event we do not have or maintain an effective registration statement, there are no circumstances that would require us to make any cash payments or net cash settle the Pre-funded Warrants to the holders.

Transferability

Subject to applicable laws, the Pre-funded Warrants may be offered for sale, sold, transferred or assigned at the option of the holder upon surrender of the Pre-funded Warrants to us together with the appropriate instruments of transfer.

Exchange Listing

There is no established trading market for the Pre-funded Warrants and we do not plan on applying to list the Pre-funded Warrants on The Nasdaq Capital Market any other national securities exchange or any other nationally recognized trading system.

Rights as a Stockholder

Except by virtue of such holder’s ownership of shares of our common stock or as otherwise set forth in the Pre-funded Warrants, the holder of a Pre-funded Warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until the holder exercises the Pre-funded Warrant.

Common Warrants to be issued in this Offering

The following summary of certain terms and provisions of the Common Warrants offered hereby is not complete and is subject to, and qualified in its entirety by the provisions of the form of the Common Warrants, which is filed as an exhibit to the registration statement of which this prospectus is a part. Prospective investors should carefully review the terms and provisions set forth in the form of the Common Warrants.

Duration and Exercise Price. Each Common Warrant offered hereby will have an initial exercise price per share equal to $[*] (equal to 100% of the combined public offering price per share of our common stock and accompanying Common Warrants). The Common Warrants will be exercisable immediately on the closing date (the “Initial Exercise Date”). The exercise price and number of shares of common stock issuable upon exercise is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. A Common Warrant to purchase one share of our common stock will be issued for every one share of common stock and Pre-funded Warrant purchased in this offering. The Common Warrants will be issued in certificated form.

Exercisability. The Common Warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the case of a cashless exercise, as discussed below). A holder (together with its affiliates) may not exercise any portion of the Common Warrant to the extent that the holder would own more than 4.99% (or, at the election of the purchaser, 9.99%) of the outstanding common stock immediately after exercise, except that upon notice from the holder to us, the holder may increase or decrease the beneficial ownership limitation up to 9.99% of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants, provided that any increase in such beneficial ownership limitation shall not be effective until 61 days following notice from the holder to us. No fractional shares of common stock will be issued in connection with the exercise of a Common Warrant. In lieu of fractional shares, we will round up to the next whole share.

Cashless Exercise. If, at the time a holder exercises its Common Warrants, a registration statement registering the issuance of the shares of common stock underlying the Common Warrants under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of shares of common stock determined according to a formula set forth in the Common Warrants.

Increase in Number of Shares Upon Reverse Stock Split. If we effect a reverse stock split after the closing of this public offering the number of shares issuable under the Common Warrants will be increased from [*] to [*] (on a pre-stock split basis).

Transferability. Subject to applicable laws, the Common Warrants may be transferred at the election of the holder upon surrender of the Common Warrant to the Company together with the appropriate instruments of transfer.

Exchange Listing. There is no established public trading market for the Common Warrants, and we do not expect a market to develop. In addition, we do not intend to list the Common Warrants on any securities exchange or nationally recognized trading system.

Fundamental Transaction. In the event of a fundamental transaction, as described in the form of Common Warrant, and generally including any reorganization, recapitalization or reclassification of our common stock, the sale, transfer or other disposition of all or substantially all of our properties or assets, our consolidation or merger with or into another person, the acquisition of more than 50% of our outstanding common stock, or any person or group becoming the beneficial owner of 50% of the voting power represented by our outstanding common stock, the holders of the Common Warrants will be entitled to receive upon exercise of the common warrants the kind and amount of securities, cash or other property that the holders would have received had they exercised the Common Warrants immediately prior to such fundamental transaction.

Warrant Agent; Global Certificate. Pursuant to warrant agent agreement between us and Vstock Transfer, LLC, as Warrant agent, the Common Warrants will be issued in book-entry form and shall initially be represented only by one or more global warrants deposited with the warrant agent, as custodian on behalf of The Depository Trust Company, or DTC, and registered in the name of Cede & Co., a nominee of DTC, or as otherwise directed by DTC.

Right as a Stockholder. Except as otherwise provided in the Common Warrants or by virtue of such holder’s ownership of shares of our common stock, the holders of the Common Warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they acquire shares of our common stock upon exercise of their Common Warrants.

UNDERWRITING

Under the terms and subject to the conditions in an underwriting agreement dated [●], 2026, the underwriter has agreed to purchase, and we have agreed to sell to it [*] shares of common stock, Pre-Funded Warrants to purchase [*] shares of common stock and Common Warrants to purchase [*] shares of common stock.

The underwriter is offering the securities subject to its acceptance of the securities from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriter to pay for and accept delivery of the securities offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriter is obligated to take and pay for all of the securities offered by this prospectus if any such securities are taken. However, the underwriter is not required to take or pay for any of the common stock or warrants covered by the underwriters’ Over-Allotment Option described below.

The underwriter initially proposes to offer part of the securities directly to the public at the offering price listed on the cover page of this prospectus and part to certain dealers. After the initial offering of the securities, the offering price and other selling terms may from time to time be varied by the underwriter.

Over-Allotment Option

We have granted the underwriter an option to buy up to an aggregate of [*] additional shares of common stock at a price per share of $[*] and/or Common Warrants to purchase up to an additional [*] shares of common stock at a price per Common Warrant of $[*], less, in each case, discounts and commissions, to cover over-allotments, if any. The underwriters have 45 days from the closing of the offering to exercise this option.

Discounts and Commissions and Expenses

We have agreed to pay the underwriters a cash fee equal to six and one-half percent (6.5%) of the aggregate gross proceeds from the sale of the securities.

The underwriter has advised us that it proposes to offer the securities directly to the public at the offering price set forth on the cover of this prospectus. In addition, the underwriter may offer some of the securities to other securities dealers at such price less a concession of up to $[●] per combined share of common stock or prefunded warrant to purchase one share of common stock and a Common Warrant to purchase one and two-tenths shares of common stock. After this public offering, the offering price and other selling terms may be changed by the underwriter without changing the Company’s proceeds from the underwriters’ purchase of the Units.

The following table shows the offering price, underwriting discounts and proceeds, before expenses, to us. The information assumes either no exercise or full exercise by the underwriter of its over-allotment option. The underwriting discounts are equal to the combined offering price per share and accompanying Common Warrants less the amount per share and accompanying Common Warrants the underwriters pay us for such securities.

Per Share and

Common
Warrants

Total without
Over-Allotment
Option

Total with
Over-Allotment
Option

Public Offering Price

Underwriting discounts (6.5%)⁽¹⁾

Proceeds, before expenses, to us

We estimate that the total expenses of this Offering, including registration, filing, and listing fees, printing fees and legal and accounting expenses, will be approximately $[●]. This figure includes expense reimbursements we have agreed to pay the underwriter for reimbursement of its accountable expenses related to this offering up to $65,000 plus a non-accountable expense allowance not to exceed 1% of the offering proceeds.

Underwriter’s Warrants

In addition, we have agreed to issue to the underwriter or its designees Underwriter Warrants to purchase up to 3% of the aggregate number of shares of common stock sold in this offering (including shares underlying any Pre-funded Warrants), at an exercise price equal to 120% of the public offering price per share to be sold in this offering. The Underwriter Warrants will be exercisable upon issuance and will expire five years from the commencement of sales under this offering. The Underwriter Warrants provide for customary adjustments for share dividends, splits and recapitalizations and the like consistent with FINRA Rule 5110. The Underwriter Warrants and the shares of common stock underlying the Underwriter Warrants are registered on the registration statement of which this prospectus is a part. The form of the Underwriter Warrant is included as an exhibit to this registration statement of which this prospectus forms a part.

Listing

Our common stock is listed on The Nasdaq Capital Market under the trading symbol “TNON.” We do not plan to list the Pre-funded Warrants or the Common Warrants on the Nasdaq Capital Market or any other securities exchange or trading market.

Lock-Up Agreements

We have agreed with the underwriter, subject to certain customary exceptions, not to sell additional equity securities for a period of 30 days after the effective date of this Offering, except that these restrictions shall not apply to any equity sales through an at-the-market facility. Pursuant to “lock-up” agreements, our executive officers, directors, and certain five percent (5.0%) security holders have agreed, subject to limited exceptions, not to directly or indirectly offer to sell, sell, pledge or otherwise transfer or dispose of any of shares of (or enter into any transaction or device that is designed to, or could be expected to, result in the transfer or disposition by any person at any time in the future of) our common stock, enter into any swap or other derivatives transaction that transfers to another, in whole or in part, any of the economic benefits or risks of ownership of shares of our common stock, make any demand for or exercise any right or cause to be filed a registration statement, including any amendments thereto, with respect to the registration of any shares of common stock or securities convertible into or exercisable or exchangeable for common stock or any of our other securities or publicly disclose the intention to do any of the foregoing, subject to customary exceptions, for a period of 60 days from the closing date of the offering.

Right of First Refusal

According to the terms of the underwriting agreement, the underwriter shall have the right of first refusal for a period of thirty (30) days after the closing of this offering to participate in each and every future public and private equity and debt offerings of the Company, or any successor to or any subsidiary of the Company. The right of first refusal granted hereunder may be terminated by us for “cause,” which shall mean a material breach by the Representative of the underwriting agreement or a material failure by the Representative to provide the services as contemplated by the underwriting agreement in which case we will not be obligated to honor the right of first refusal.

Tail

We have also agreed to pay the underwriter a tail fee equal to the cash and warrant compensation in this offering, if any investor, who was contacted by the underwriter or who was brought over-the-wall during the term of its engagement, provides us with capital in any public or private offering or other financing or capital raising transaction of any kind during the six-month period following the closing of this public offering or the expiration or termination of our engagement of the underwriter.

Indemnification

We have agreed to indemnify the underwriter against specified liabilities, including liabilities under the Securities Act, and to contribute to payments the underwriters may be required to make in respect thereof.

Electronic Offer, Sale and Distribution of Securities

A prospectus in electronic format may be made available on a website maintained by WallachBeth and may also be made available on a website maintained by other underwriters. WallachBeth may agree to allocate a number of shares and warrants to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by WallachBeth to underwriters that may make internet distributions on the same basis as other allocations. In connection with this offering, the underwriter or syndicate members may distribute prospectuses electronically. No forms of electronic prospectus other than prospectuses that are printable as Adobe^® PDF will be used in connection with this offering.

The underwriter has informed us that it does not expect to confirm sales of securities offered by this prospectus to accounts over which they exercise discretionary authority.

Other than the prospectus in electronic format, the information on any underwriter’s website and any information contained in any other website maintained by an underwriter is not part of the prospectus or the registration statement of which this prospectus forms a part, has not been approved and/or endorsed by us or any underwriter in its capacity as underwriter and should not be relied upon by investors.

Certain Relationships

The underwriter and its affiliates have provided and may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates for which they have or may in the future receive customary fees, however, except for the right of first refusal disclosed in this prospectus, we have no present arrangements with any of the underwriters for any further services.

The underwriter and certain of its affiliates are full service financial institutions engaged in, and may in the future engage in, various activities, which may include securities trading, investment banking and other commercial dealings, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriter and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. In addition, from time to time, the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future.

In the ordinary course of its various business activities, the underwriter and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriter or its affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the Common Stock offered hereby. Any such short positions could adversely affect future trading prices of the Common Stock offered hereby. The underwriters and certain of their affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

Selling Restrictions

Other than in the United States of America, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions relating to the Offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a solicitation is unlawful.

Transfer Agent

The transfer agent and registrar for our Common Stock is Vstock Transfer, LLC. The transfer agent and registrar’s address is 18 Lafayette Place, Woodmere, New York 11598.

EXPERTS

The financial statements of Tenon Medical, Inc. as of and for the years ended December 31, ~~2024~~2025 and ~~2023~~December 31, 2024 have been incorporated by reference herein and in ~~this~~the ~~prospectus~~registration statement in reliance upon the report of Haskell & White LLP, an independent registered public accounting firm, ~~upon~~given on the authority of said firm as experts in auditing and accounting. The report of Haskell & White LLP on the financial statements of Tenon Medical, Inc. as of and ~~auditing~~for the years ended December 31, 2025 and December 31, 2024 contains an explanatory paragraph expressing substantial doubt regarding the Company’s ability to continue as a going concern.

LEGAL MATTERS

Certain legal matters with respect to the validity of the securities being offered by this prospectus will be passed upon by Sichenzia Ross Ference Carmel LLP, New York, New York. The underwriter is being represented by Sheppard, Mullin, Richter & Hampton LLP, New York, New York, in connection with this offering.

~~WHERE~~INCORPORATION ~~YOU~~OF ~~CAN~~CERTAIN ~~FIND~~INFORMATION ~~MORE~~BY ~~INFORMATION~~REFERENCE

We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of our common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, some of which is contained in exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. You may obtain copies of this information by mail from the Public Reference Section of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549, at prescribed rates. You may obtain information on the operation of the public reference rooms by calling the SEC at 1-800-SEC-0330. The SEC also maintains an Internet website that contains reports, proxy statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov.

We are subject to the information and reporting requirements of the Exchange Act and, in accordance with this law, are required to file periodic reports, proxy statements and other information with the SEC. These periodic reports, proxy statements and other information are available for inspection and copying at the SEC’s public reference facilities and the website of the SEC referred to above. We also maintain a website at www.tenonmed.com. You may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.

INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE

The SEC allows us to incorporate by reference much of the information that we file with the SEC, which means that we can disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. This prospectus incorporates by reference the documents listed below (other than any portions of such documents that are not deemed “filed” under the Exchange Act in accordance with the Exchange Act and applicable SEC rules):

● our Annual Report on Form 10-K for the year ended December 31, ~~2024~~2025, filed with the SEC on March 2627, ~~2025~~2026;

● ~~Our~~our ~~Current~~Quarterly ~~Reports~~Report on Form 810-K,Q ~~filed~~for the fiscal quarter ended March 1231, ~~2025~~2026, ~~March~~filed ~~27,~~with ~~2025~~the ~~and~~SEC ~~March~~on 28May 15, ~~2025~~2026;

	●	our Current Reports on Form 8-K filed with the SEC on February 27, 2026, March 17, 2026, May 22, 2026, June 11, 2026, and June 12, 2026;

	●	our preliminary proxy statement on Schedule 14A filed with the SEC on June 12, 2026;

●

the description of our common stock contained in the Registration Statement on Form 8A12B (File No. 001-41364) relating thereto, filed on April 26, 2022, including any amendment or report filed for the purpose of updating such description; and

●

any future filings made with the SEC under Section 13(a), 13(c) or 15(d) of the Exchange Act.

~~Certain~~All reports ~~statements~~and inother documents that we subsequently file with the SEC (other than any portion of such filings that are furnished under applicable ~~and~~SEC ~~portions~~rules rather than filed) pursuant to Section 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus ~~update~~ and before ~~replace~~the ~~information~~later inof: (1) the ~~above~~completion ~~listed~~of ~~documents~~the ~~incorporated~~offering byof ~~reference.~~our ~~Likewise~~shares of common stock pursuant to this prospectus, ~~statements~~and (2) the date we instop oroffering ~~portions~~our shares of acommon ~~future~~stock ~~document~~pursuant to this prospectus, will be deemed to be incorporated by reference ininto this prospectus and ~~may~~to ~~update~~be ~~and~~part ~~replace~~of ~~statements~~this inprospectus ~~and~~from ~~portions~~the date of ~~this~~ ~~prospectus~~filing orof ~~the~~such ~~above~~reports ~~listed~~and documents.

You should not assume that the information in this prospectus or any document incorporated by reference is accurate as of any date other than the date of the applicable document. Any statement contained in a document incorporated or deemed to be incorporated by reference into this prospectus will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or any other subsequently filed document that is incorporated or deemed to be incorporated by reference into this prospectus modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus.

We will provide you without charge, upon your written or oral request, a copy of any of the documents incorporated by reference in this prospectus, other than exhibits to such documents which are not specifically incorporated by reference into such documents. Please direct your written or telephone requests to:

Tenon Medical, Inc.

Attn: Chief Financial Officer

104 Cooper Court

Los Gatos, California 95032

Telephone: (408) 649-5760

16The information contained on our website is not a part of this prospectus.

WHERE YOU CAN FIND MORE INFORMATION

We are subject to the informational requirements of the Exchange Act and in accordance therewith file annual, quarterly and current reports, proxy statements and other information with the Securities and Exchange Commission. The Securities and Exchange Commission maintains a website that contains reports, proxy and information statements and other information regarding registrants that file electronically with the Securities and Exchange Commission. The address of the Securities and Exchange Commission’s website is www.sec.gov.

We make available free of charge on or through our website at www.tenonmed.com, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after we electronically file such material with or otherwise furnish it to the Securities and Exchange Commission.

We have not incorporated by reference into this prospectus the information on our website, and you should not consider it to be a part of this prospectus.

1,812,987 shares of Common Stock

Common Stock Purchase Warrants to Purchase up to 6,975,584 shares of Common Stock

Pre-funded Warrants to Purchase up to 4,000,000 shares of Common Stock

Up to 6,975,584 shares of Common Stock underlying the Common Stock Purchase Warrants

Up to 4,000,000 shares of Common Stock underlying the Pre-funded Warrants

Tenon Medical, Inc.

5,673,550 Shares of Common Stock

PROSPECTUS

____________________, ~~2025~~ 2026

Part II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 13. Other Expenses of Issuance and Distribution.

The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than ~~placement~~underwriter ~~agent~~discounts ~~fees~~ and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee and the Financial Industry Regulatory Authority, Inc., or FINRA filing.

	Amount
Securities and Exchange Commission registration fee	$	1,~~316~~409.0064
Accountants’ fees and expenses	$	7,500
FINRA filing fee	$	1,741.63
Legal fees and expenses	$	60,000.00
Accountants’ fees and expenses	$	15,000.00
Printing and engraving expenses	$	10,000.00
Legal fees and expenses	$	125,000.00
Miscellaneous	$	0.00
Printing and engraving expenses	$	5,000.00
Total expenses	$	78,816.00
Miscellaneous	$	51,848.73
Total expenses	$	200,000.00

Item 14. Indemnification of Directors and Officers.

Section 102 of the General Company Law of the State of Delaware (“DGCL”) permits a Company to eliminate the personal liability of directors of a Company to the Company or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our ~~charter,~~amended asand ~~amended~~ restated certificate of incorporation provides that no director of the Company shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty.

Section 145 of the DGCL provides that a Company has the power to indemnify a director, officer, employee, or agent of the Company, or a person serving at the request of the Company for another Company, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the Company, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the Company unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper.

Our charter, as amended provides that we will indemnify to the fullest extent permitted from time to time by the DGCL or any other applicable laws as presently or hereafter in effect, any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative, including, without limitation, an action by or in the right of the Company, by reason of his acting as a director or officer of the Company or any of its subsidiaries (and the Company, in the discretion of the Board of Directors, may so indemnify a person by reason of the fact that he is or was an employee or agent of the Company or any of its subsidiaries or is or was serving at the request of the Company in any other capacity for or on behalf of the Company) against any liability or expense actually and reasonably incurred by such person in respect thereof; provided, however, the Company shall be required to indemnify an officer or director in connection with an action, suit or proceeding (or part thereof) initiated by such person only if (i) such action, suit or proceeding (or part thereof) was authorized by the Board of Directors and (ii) the indemnification does not relate to any liability arising under Section 16(b) of the Exchange Act, as amended, or any rules or regulations promulgated thereunder. Such indemnification is not exclusive of any other right to indemnification provided by law or otherwise.

II-1

If a claim is not paid in full by the Company, the claimant may at any time thereafter bring suit against the Company to recover the unpaid amount of the claim and, if successful in whole or in part, the claimant shall be entitled to be paid also the expense of prosecuting such claim. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in defending any proceeding in advance of its final disposition where any undertaking required by the By-laws of the Company has been tendered to the Company) that the claimant has not met the standards of conduct which make it permissible under the DGCL for the Company to indemnify the claimant for the amount claimed, but the burden of proving such defense shall be on the Company. Neither the failure of the Company (including its Board of Directors, legal counsel, or its stockholders) to have made a determination prior to the commencement of such action that indemnification of the claimant is proper in the circumstances because he or she has met the applicable standard of conduct set forth in the DGCL, nor an actual determination by the Company (including its Board of Directors, legal counsel, or its stockholders) that the claimant has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that the claimant has not met the applicable standard of conduct. Indemnification shall include payment by the Company of expenses in defending an action or proceeding in advance of the final disposition of such action or proceeding upon receipt of an undertaking by the person indemnified to repay such payment if it is ultimately determined that such person is not entitled to indemnification.

~~In any underwriting agreement we enter into in~~Item ~~connection~~15. ~~with~~Recent ~~the~~Sales ~~sale~~ of ~~common~~Unregistered ~~stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the~~ Securities ~~Act of 1933, as amended, or the Securities Act, against certain liabilities~~.

~~Item~~Set forth ~~15.~~below ~~Recent~~is ~~Sales~~information regarding shares of ~~Unregistered~~capital stock issued by us within the last three years which was not registered under the Securities Act of 1933, as amended.

~~Set forth below is information regarding shares~~(a) ofIssuance ~~capital stock issued by us within the last three years which was not registered under the Securities Act~~ of ~~1933,~~Capital ~~as amended~~Stock.

~~(a)~~Common Stock ~~Issuance~~and ofPreferred ~~Capital~~ Stock.

~~Common~~In April ~~Stock~~2022, ~~and~~we ~~Preferred~~issued ~~Stock~~3,905 shares of common stock to SpineSource, Inc. The shares of common stock had a value of $400.00 per share.

In February ~~April 2022~~2024, we issued ~~3,905~~a ~~shares~~total of ~~common stock to SpineSource~~256,968 ~~Inc. The~~ shares of ~~common~~Series ~~stock~~A ~~had~~Preferred aStock ~~value~~to ~~of $400~~investors.~~00 per share.~~

In July ~~February 2024~~2023, we ~~issued~~completed a ~~total~~private ofplacement ~~256~~to Lincoln Park Capital Fund,~~968~~ LLC (“Lincoln Park”) pursuant to which we have the right to sell to Lincoln Park up to $10.0 million in shares of ~~Series~~common Astock, ~~Preferred~~subject ~~Stock~~to certain limitations, from time to ~~investors~~time over the 24-month period commencing on the date that a registration statement covering the resale of the shares is declared effective by the SEC. We issued 12,364 Commitment Shares to Lincoln Park as consideration for its commitment to purchase our shares under the Purchase Agreement. In the Purchase Agreement, Lincoln Park represented to us, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act). The securities were and will be sold by us under the Purchase Agreement in reliance upon an exemption from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.

In February ~~July 2023~~2024, we ~~completed~~issued a11,231 ~~private~~shares ~~placement~~ to Lincoln Park ~~Capital Fund, LLC (“Lincoln Park”)~~ pursuant to ~~which we have the right to sell to Lincoln Park up to $10.0 million in shares of common stock, subject to certain limitations, from time to time over the 24-month period commencing on the date that~~ a ~~registration statement covering the resale of the shares is declared effective by the SEC. We issued 12,364 Commitment Shares to Lincoln Park as consideration for its commitment to~~ purchase ~~our~~facility ~~shares~~with ~~under the Purchase Agreement. In the Purchase Agreement,~~ Lincoln Park ~~represented to us, among other things, that it was an “accredited investor” (as such term is defined in Rule 501(a) of Regulation D under the Securities Act)~~. The securities were and will be sold by us under the Purchase Agreement in reliance upon an exemption from the registration requirements under the Securities Act afforded by Section 4(a)(2) of the Securities Act.

In July ~~February~~ 2024, we issued 1121,~~231~~368 shares to Lincoln Park pursuant to a purchase facility with Lincoln Park.

In August ~~July~~ 2024, we issued 2116,~~368~~250 ~~shares~~ to Lincoln Park pursuant to a purchase facility with Lincoln Park.

In ~~August~~ September 2024, we issued ~~16,250~~a tototal ~~Lincoln~~of ~~Park pursuant~~86,454 toshares aof ~~purchase~~Series ~~facility~~B ~~with~~Preferred ~~Lincoln~~Stock ~~Park~~to investors.

In August ~~September 2024~~2025, we issued aSiVantage, ~~total~~Inc. of(“SiVantage”) 86710,~~454~~300 shares of ~~Series~~the BCompany’s ~~Preferred~~common stock, of which 473,533 ~~Stock~~are to ~~investors~~be held by the Company for a period of one-year as security to satisfy any indemnification claims against SiVantage in accordance with the asset purchase agreement by and between the Company and SiVantage, dated as of August 1, 2025 (“SI APA”).

~~II-2~~In August 2025, we issued each of Mr. Geist, our Chief Innovation Officer, and Mr. Grawey, our Chief Commercial Officer, 138,114 shares of common stock of the Company (subject to vesting terms) in accordance with their respective employment agreements with the Company.

~~The~~In November ~~issuance~~2025, ofwe ~~the~~issued ~~capital~~certain ~~stock~~accredited ~~listed~~investors ~~above was~~(the ~~deemed~~“Purchasers”), ~~exempt~~including ~~from~~Mr. ~~registration~~Geist ~~under~~and ~~Section~~Mr. ~~4(a)(2)~~Grawey, an aggregate of ~~the~~2,217,904 ~~Securities~~shares ~~Act~~of orcommon ~~Regulation~~stock Dof ~~promulgated~~the ~~thereunder~~Company inand ~~that~~Warrants ~~the~~(as ~~issuance of~~described ~~securities~~below), ~~were~~at ~~made~~a tocombined anoffering ~~accredited~~price ~~investor~~of $1.285 per share and ~~did~~warrant ~~not~~to ~~involve~~purchase aone ~~public~~share ~~offering.~~of ~~The~~common ~~recipient~~stock, ofpursuant ~~such~~to the securities ~~represented its~~purchase ~~intention~~agreements tosigned ~~acquire~~by the ~~securities~~Company ~~for~~and ~~investment~~Purchasers on ~~purposes~~November ~~only~~10, ~~and~~2025 ~~not~~(“November ~~with~~2025 aPIPE ~~view~~Financing”). toThe orCompany ~~for~~issued ~~sale~~such securities in ~~connection~~reliance ~~with~~on ~~any~~the ~~distribution~~exemption from ~~thereof~~registration provided by Section 4(a)(2) and Regulation 506(b) under the Securities Act.

~~(b)~~In November ~~Option~~2025, ~~Grants~~we issued our employee 6,554 shares of common stock pursuant to Tenon Medical, Inc. 2022 Equity Incentive Plan, as amended.

OnIn January ~~August 10~~2026, ~~2021~~we ~~the~~issued ~~Company~~our ~~issued~~directors aand ~~total of~~officers ~~263~~an ~~options~~aggregate to433,321 ~~various~~shares ~~individuals~~of atcommon anstock ~~exercise~~upon ~~price~~conversion of ~~$564.80~~50% ~~per~~restricted ~~share.~~stock units ~~The~~issued ~~options~~on ~~are~~October ~~subject~~13, 2025, pursuant to ~~equal~~the ~~monthly~~Tenon ~~vesting~~Medical, ~~over a~~Inc. ~~two~~2022 orEquity ~~three-year~~Incentive ~~period~~Plan.

On May ~~October~~1, 82026, ~~2021~~we ~~the Company~~ issued a276,228 ~~total~~ shares of ~~275~~our ~~options~~common stock to ~~various~~SiVantage, ~~individuals~~pursuant atto anthe ~~exercise~~SI ~~price~~APA, ofin ~~$600.00~~connection ~~per~~with ~~share.~~the ~~The~~achievement ~~options are subject to equal monthly vesting over~~of a ~~two~~certain ormilestone ~~three-year~~set ~~period~~forth therein.

The issuance ~~options~~of ~~described~~the capital stock listed above ~~were~~was deemed exempt from registration inunder ~~reliance on~~ Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities were made to an accredited investor and did not involve a public offering. The ~~recipients~~recipient of such securities represented its intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof.

~~(c) Warrants.~~II-2

~~In April 2022, in connection with the Company’s~~(b) ~~initial~~Option ~~public offering, the Company granted the Underwriters warrants to purchase a total of 1,200 shares of the Company’s common stock~~Grants. ~~The warrants are immediately exercisable at an exercise price of $400.00 per share and expire on the fifth anniversary of the commencement of sales under the IPO.~~

InOn August ~~November 2023~~10, we2021 ~~issued~~the ~~warrants~~Company toissued ~~purchase 5,625~~a ~~shares~~total of ~~our~~263 ~~common~~options ~~stock~~to various individuals at an exercise price ~~equal~~of to $15564.5280 per share. The options are subject to ~~investors~~equal monthly vesting over a two or three-year period.

InOn October ~~February 2024~~8, we2021 ~~issued~~the ~~warrants~~Company toissued ~~purchase 51,934~~a ~~shares~~total of ~~our~~275 ~~common~~options ~~stock~~to various individuals at an exercise price ~~equal~~of to $10600.~~164~~00 per share. The options are subject to ~~investors~~equal monthly vesting over a two or three-year period.

InThe options ~~September~~described ~~2024,~~above wewere ~~issued~~deemed ~~warrants~~exempt tofrom ~~purchase~~registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated ~~16,214~~thereunder ~~shares~~in that the issuance of ~~our~~securities ~~common~~were ~~stock~~made atto an ~~exercise~~accredited ~~price~~investor ~~equal~~and todid $4not involve a public offering.~~2756~~ ~~per~~The ~~share~~recipients of such securities represented its intention to ~~investors~~acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof.

~~In September 2024, we issued warrants to purchase~~(c) ~~2,445,700 shares of our common stock at an exercise price equal to $4~~Warrants.~~28 per share.~~

OnIn April ~~March 12~~2022, ~~2025~~in connection with the Company’s initial public offering, wethe ~~issued~~Company granted the Underwriters warrants to purchase a 3total of 1,~~668,550~~200 shares of ~~our~~the Company’s common stock. The warrants are immediately exercisable at an exercise price of $1400.25 00 per share and expire on the fifth anniversary of the commencement of sales under the IPO.

OnIn November ~~March 26~~2023, ~~2025,~~ we issued warrants to purchase ~~733~~5,~~500~~625 shares of our common stock at an exercise price ofequal to $215.0052 per share to investors.

OnIn February ~~March 27~~2024, ~~2025,~~ we issued warrants to purchase 1 51,~~271,500~~934 shares of our common stock at an exercise price ofequal to $210.00164 per share to investors.

~~The~~In September ~~warrant~~2024, ~~described~~we ~~above~~issued ~~were~~warrants ~~deemed~~to ~~exempt from~~purchase ~~registration~~16,214 inshares ~~reliance on Section 4(a)(2)~~ of ~~the~~our ~~Securities~~common ~~Act~~stock orat ~~Regulation~~an Dexercise ~~promulgated~~price ~~thereunder~~equal ~~in that the issuance of securities were made~~ to ~~an accredited investor and did not involve a public offering~~$4.2756 ~~The~~per ~~recipients~~share ~~of such securities represented its intention~~ to ~~acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof~~investors.

~~(d)~~In September ~~Issuance~~2024, we issued warrants to purchase 2,445,700 shares of ~~Notes~~our common stock at an exercise price equal to $4.28 per share.

~~None~~On March 12, 2025, we issued warrants to purchase 3,668,550 shares of our common stock at an exercise price of $1.25 per share.

~~II-3~~On March 26, 2025, we issued warrants to purchase 733,500 shares of our common stock at an exercise price of $2.00 per share.

~~Item~~On March ~~16.~~27, ~~Exhibits~~2025, ~~and~~we ~~Financial~~issued ~~Statement~~warrants ~~Schedules~~to purchase 1,271,500 shares of our common stock at an exercise price of $2.00 per share.

In November 2025, in connection with the November 2025 PIPE Financing, we issued the Purchasers, including Mr. Geist and Mr. Grawey, an aggregate of 2,217,904 common stock purchase warrants (the “Warrants”), each exercisable for one share of common stock of the Company, at a combined offering price of $1.285 per Share and Warrant to purchase one share of common stock. The Warrants have an exercise price of $1.16 per share and expire three years from the date of issuance. The Company issued such securities in reliance on the exemption from registration provided by Section 4(a)(2) ~~Exhibits:~~and Regulation 506(b) under the Securities Act.

~~EXHIBIT~~The warrants ~~INDEX~~described above were deemed exempt from registration in reliance on Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that the issuance of securities were made to an accredited investor and did not involve a public offering. The recipients of such securities represented its intention to acquire the securities for investment purposes only and not with a view to or for sale in connection with any distribution thereof.

Exhibit No.		Description
3.1		Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-271648, filed on May 4, 2023)
3.2		Bylaws of the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-260931, filed on April 20, 2022)
3.3		Certificate of Designations, Rights and Preferences for Series A Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
3.4		Amendment to Certificate of Designations, Rights and Preferences for Series A Preferred Stock (incorporated by reference to the Registrant’s Registration Statement No. 333-281531, filed on September 9, 2024)
3.5		Certificate of Designations, Rights and Preferences for Series B Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
4.1		Form of Representative’s Warrant in connection with the Registrant’s Initial Public Offering (incorporated by reference to the Registrant’s Registration Statement No. 333-260931, filed on April 15, 2022)
4.2		Form of publicly traded Warrant issued on June 16, 2023 (Incorporated by reference to exhibit 4.1 the Registrant’s Registration Statement No. 333-272488, filed on June 7, 2023)
4.3		Form of Warrant Agency Agreement between the Company and VStock Transfer, LLC (incorporated by reference to exhibit 4.3 to the Registrant’s Registration Statement No. 333-272488, filed on June 7, 2023)
4.4		Form of Warrant issued to investors on November 21, 2023 (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on November 28, 2023)
4.5		Form of Warrant issued to investors in the Series A Preferred Stock on February 20, 2024 (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
4.6		Form of Warrant issued to the investors in the Series B Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
4.7		Description of Securities of the Registrant (incorporated by reference to the Registrant’s 8-A12B Registration Statement, filed on April 26, 2022)
4.8		Form of Series C-1 Warrant (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
4.9		Form of Series C-2 Warrant (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
5.1		Opinion of Legal Counsel to the Registrant
10.1##		Employment Agreement dated June 1, 2021 between Steven M. Foster and the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-260931, filed on April 20, 2022)
10.2##		Employment Agreement dated June 1, 2021 between Richard Ginn and the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-260931, filed on April 20, 2022)
10.3##		Consulting Agreement dated May 7, 2021 by and between Richard Ferrari and the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-260931, filed on April 20, 2022)
10.4		Tennon Medical 2022 Equity Incentive Plan (incorporated by reference to the Registrant’s Registration Statement No. 333-271648, filed on May 4, 2023)
10.5		Form of Securities Purchase Agreement between the Registrant and Lincoln Park Capital Fund, LLC (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on July 28, 2023)
10.6		Form of Securities Purchase Agreement entered into between the Registrant and investors in the Series A Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
10.7		Form of Securities Purchase Agreement entered into between the Registrant and investors in the November 2023 Notes (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on November 28, 2023)
10.8		Form of Securities Purchase Agreement entered into between the Registrant and investors in the Series B Preferred Stock (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
10.9		Form of Inducement Letter, dated March 11, 2025 (incorporated by reference to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
19.1		Insider Trading Policy (incorporated by reference to the Registrant’s Annual Report on Form 10-K, filed on March 29, 2024)
21.1		List of Subsidiaries of the Registrant (incorporated by reference to the Registrant’s Registration Statement No. 333-281531, filed on September 9, 2024)
23.1		Consent of Haskell & White LLP
23.2		Consent of Counsel to Registrant (included in Exhibit 5.1).
24.1		Power of Attorney (included on the signature page hereto)
107		Filing Fee Table.

(d) Issuance of Notes.

##In March ~~Denotes~~2026, ~~management~~we ~~compensation~~issued ~~plan~~certain accredited investors 20% Original Issue Discount Senior Convertible Promissory Notes in an aggregate principal amount of $4.3 million in a private placement 20 (the “Notes”) for aggregate gross proceeds of approximately $4.3 million before deducting fees and expenses of the underwriter. The Notes have a maturity date of September 11, ~~agreement~~2026 or(which ~~arrangement~~can be extended at the option of the Company until December 11, 2026) and are convertible, following the six month anniversary of the issuance date, into shares of the Company’s common stock at a conversion price equal to 80% of the VWAP for the three (3) Trading Days immediately prior to the date of conversion, subject to adjustment as provided in the Notes.

~~(b)~~The issuance ~~Financial~~of ~~Statement Schedules:~~the ~~All~~Notes ~~schedules~~was ~~are~~made ~~omitted~~pursuant ~~because~~to the ~~required~~exemption ~~information~~from isthe ~~inapplicable~~registration orrequirements under the ~~information~~Securities isAct ~~presented~~available into the ~~financial~~ ~~statements~~Company under Section 4(a)(2) and/or Regulation D promulgated thereunder due to the ~~related~~fact ~~notes~~the offering of the Notes did not involve a public offering of securities.

~~II-4~~(e) Issuance of Restricted Stock Units.

~~Item~~In October 172025, we issued our directors and officers an aggregate 866,642 restricted stock units (“RSUs”) pursuant to the Tenon Medical, Inc. ~~Undertakings~~2022 Equity Incentive Plan, as amended, vesting and automatically converting into the shares of common stock of the Company on one-for-one basis in two installments: 50% on January 1, 2026, and 50% on July 31, 2026.

The Company ~~undersigned~~issued ~~registrant~~the ~~hereby~~RSUs ~~undertakes:~~as described above in reliance on exemption from the registration requirements of the Securities Act, available to the Company under Section 4(a)(2) of the Securities Act due to the fact that the issuance did not involve a public offering of securities.

~~The undersigned registrant hereby undertakes:~~II-3

~~(1) To file, during any period~~Item in16. ~~which~~Exhibits ~~offers~~and orFinancial ~~sales~~Statement ~~are being made, a post-effective amendment to this registration statement:~~Schedules.

(~~i) To include any prospectus required by section 10(~~a)~~(3) of the Securities Act of 1933, as amended (the “Securities Act”);~~ Exhibits:

~~(ii) To reflect in the prospectus~~EXHIBIT any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; andINDEX

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement; provided, however, that paragraphs (1)(i), (1)(ii) and (1)(iii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in the registration statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the registration statement.

Exhibit No.		Description
1.1		Form of Underwriting Agreement
3.1		Second Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to exhibit 3.1 to the Registrant’s Registration Statement on Form S-3 No. 333-271648, filed on May 4, 2023)
3.2		Certificate of Correction to Second Amended and Restated Certificate of Incorporation of the Registrant, filed on October 25, 2023 (incorporated by reference to exhibit 4.2 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.3		Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on November 1, 2023 (incorporated by reference to exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on November 7, 2023)
3.4		Amendment to Certificate of Incorporation Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of the Registrant, filed on September 4, 2024 (incorporated by reference to exhibit 4.4 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.5		Certificate of Designations, Rights and Preferences for Series A Preferred Stock of the Registrant, filed on February 20, 2024 (incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
3.6		Amendment to Certificate of Designations, Rights and Preferences for Series A Preferred Stock, filed on September 5, 2024 (incorporated by reference to exhibit 4.6 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.7		Certificate of Designations, Rights and Preferences for Series B Preferred Stock, filed on September 5, 2024 (incorporated by reference to exhibit 4.7 to the Registrant’s Registration Statement on Form S-8 No. 333-290808, filed on October 10, 2025)
3.8		Bylaws of the Registrant (incorporated by reference to exhibit 3.2 to the Registrant’s Registration Statement on Form S-1/A No. 333-260931, filed on April 20, 2022)
3.9		Amendment No. 1 to the Bylaws of Tenon Medical, Inc. (incorporated by reference to exhibit 3.1 to the Registrant’s Current Report on Form 8-K, filed on June 11, 2026)
4.1		Form of Representative’s Warrant in connection with the Registrant’s Initial Public Offering (incorporated by reference to exhibit 4.1 to the Registrant’s Registration Statement on Form S-1/A No. 333-260931, filed on April 15, 2022)
4.2		Form of publicly traded Warrant issued on June 16, 2023 (incorporated by reference to exhibit 4.1 the Registrant’s Registration Statement on Form S-1 No. 333-272488, filed on June 7, 2023)
4.3		Form of Warrant Agency Agreement between the Company and Vstock Transfer, LLC (incorporated by reference to exhibit 4.3 to the Registrant’s Registration Statement on Form S-1 No. 333-272488, filed on June 7, 2023)
4.4		Form of Warrant issued to investors on November 21, 2023 (incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on November 28, 2023)
4.5		Form of Warrant issued to investors in the Series A Preferred Stock on February 20, 2024 (incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on February 22, 2024)
4.6		Form of Warrant issued to the investors in the Series B Preferred Stock (incorporated by reference to exhibit 10.3 to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
4.7		Description of Securities of the Registrant – Common Stock (incorporated by reference to the Registrant’s 8-A12B Registration Statement, filed on April 26, 2022)
4.8		Description of Securities of the Registrant – Warrants (incorporated by reference to the Registrant’s 8-A12B Registration Statement, filed on June 14, 2023)
4.9		Form of Series A Warrants issued in September 2024 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2024)
4.10		Form of Series B Warrants issued in September 2024 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on September 16, 2024

~~(2) That, for the purpose of determining any liability under the Securities Act, each such post~~II-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.4

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

4.11		Form of Series C-1 Warrant (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
4.12		Form of Series C-2 Warrant (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on March 12, 2025)
4.13		Form of Common Warrants, issued on March 26, 2025 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
4.14		Form of Pre-Funded Warrants issued on March 26, 2025 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
4.15		Form of Common Warrants, issued on March 27, 2025 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
4.16		Form of Pre-Funded Warrants issued on March 27, 2025 (incorporated by reference to exhibit 4.2 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
4.17		Form of Common Stock Purchase Warrant, dated November 13, 2025 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on November 17, 2025)
4.18		Form of Senior Convertible Promissory Notes, dated March 11, 2026 (incorporated by reference to exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed on March 17, 2026)
4.19		Form of Common Stock Purchase Warrant
4.20		Form of Pre-funded Warrant
4.21		Form of the Underwriter’s Warrant
5.1		Opinion of Legal Counsel to the Registrant
10.1#		Employment Agreement dated June 1, 2021 between Steven M. Foster and the Registrant (incorporated by reference to exhibit 10.15 the Registrant’s Registration Statement on Form S-1 No. 333-260931, filed on November 10, 2021)
10.2#		Employment Agreement dated June 1, 2021 between Richard Ginn and the Registrant (incorporated by reference to exhibit 10.16 to the Registrant’s Registration Statement on Form S-1 No. 333-260931, filed on November 10, 2021)
10.3#		Consulting Agreement dated May 7, 2021 by and between Richard Ferrari and the Registrant (incorporated by reference to exhibit 10.17 to the Registrant’s Registration Statement on Form S-1 No. 333-260931, filed on November 10, 2021)
10.4#		Offer Letter dated as of August 16, 2024, issued by the Company to Kevin Williamson (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 27, 2024)
10.5#		Form of Employment Agreement between Tenon Medical Inc. and Wyatt Geist, dated August 1, 2025 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)
10.6#		Form of Employment Agreement between Tenon Medical Inc. and Nate Grawey, dated August 1, 2025 (incorporated by reference to exhibit 10.2 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)
10.4		Tenon Medical 2022 Equity Incentive Plan (incorporated by reference to exhibit 10.30 to the Registrant’s Registration Statement on Form S-1/A No. 333- 260931, filed on April 20, 2022)
10.5		Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of July 23, 2024 (incorporated by reference to exhibit 4.10 to the Registrant’s Registration Statement on Form S-8 No. 333-293417, filed on February 12, 2026)
10.6		Amendment to Tenon Medical, Inc. 2022 Equity Incentive Plan, dated as of September 18, 2025 (incorporated by reference to exhibit 4.10 to the Registrant’s Registration Statement on Form S-8 No.333-290808, filed on October 10, 2025)
10.7		Asset Purchase Agreement between Tenon Medical Inc. and SiVantage Inc., dated August 1, 2025 (incorporated by reference to exhibit 2.1 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)
10.8		Asset Purchase Agreement between Tenon Medical Inc. and SIMPL Medical, LLC, dated August 1, 2025 (incorporated by reference to exhibit 2.2 to the Registrant’s Current Report on Form 8-K, filed on August 7, 2025)

~~(4) That, for the purpose of determining liability under the Securities Act to any purchaser:~~II-5

(A) Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and

10.9		Form of Securities Purchase Agreement entered into between the Registrant and investors in the Series B Preferred Stock financing (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on September 6, 2024)
10.10		Form of Securities Purchase Agreement, dated as of March 25, 2025, by and between the Company and the purchasers listed on the signature pages thereto (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 27, 2025)
10.11		Form of Securities Purchase Agreement, dated as of March 25, 2025, by and between the Company and the purchasers listed on the signature pages thereto (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 28, 2025)
10.12		Form of Securities Purchase Agreement, dated November 10, 2025, between Tenon Medical Inc. and Purchasers (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on November 17, 2025)
10.13		Form of Securities Purchase Agreement, dated March 11, 2026, between Tenon Medical, Inc. and Purchasers (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed on March 17, 2026)
10.14#		Amendment to the Consulting Agreement, dated May 7, 2021, by and between Tenon Medical, Inc. and Richard Ferrari, dated as of May 7, 2026 (incorporated by reference to exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on June 12, 2026).
10.15		Form of Warrant Agency Agreement
21.1		List of Subsidiaries of the Registrant (incorporated by reference to exhibit 21.1 to the Registrant’s Registration Statement on Form S-1/A No. 333-281531, filed on September 9, 2024)
23.1		Consent of Haskell & White LLP
23.2		Consent of Counsel to Registrant (included in Exhibit 5.1).
24.1		Power of Attorney (included on the signature page hereto)
107		Filing Fee Table.

~~(B)~~# ~~Each~~Denotes ~~prospectus~~management ~~filed pursuant~~compensation ~~to Rule 424(b) as part of a registration statement relating to an offering~~plan, ~~other~~agreement ~~than registration statements relying on Rule 430B~~ or ~~other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness~~arrangement. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

~~II-5~~(b) Financial Statement Schedules: All schedules are omitted because the required information is inapplicable or the information is presented in the financial statements and the related notes.

(5) That for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution of securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:II-6

~~(i) Any preliminary prospectus~~Item or17. ~~prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;~~Undertakings.

~~(ii) Any free writing prospectus~~The ~~relating to the offering prepared by or on behalf of the~~ undersigned registrant orhereby ~~used or referred to by the undersigned registrant;~~undertakes:

~~(iii)~~ The ~~portion of any other~~ ~~free writing prospectus relating to the offering containing material information about the~~ undersigned registrant orhereby ~~its securities provided by or on behalf of the undersigned registrant; and~~undertakes:

(iv1) To ~~Any~~file, ~~other~~during ~~communication that~~any isperiod anin ~~offer~~which inoffers ~~the~~or ~~offering~~sales ~~made~~are bybeing ~~the~~made, ~~undersigned~~a ~~registrant~~post-effective amendment to ~~the~~this ~~purchaser.~~registration statement:

~~Insofar as indemnification for liabilities arising~~(i) ~~under~~To ~~the~~include ~~Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to~~ any ~~charter~~prospectus ~~provision, by~~required law or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than payment by ~~the~~section ~~registrant of expenses incurred or paid by~~ 10(a ~~director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding~~)(3) ~~is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion~~ of ~~its counsel~~ the ~~matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the~~ Securities Act ~~and will be governed by the final adjudication of such issue.~~;

~~The~~(ii) To ~~undersigned~~reflect ~~registrant~~in ~~hereby~~the ~~undertakes~~prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that: which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and

(1iii) To ~~For~~include ~~purposes~~any ofmaterial ~~determining any~~information ~~liability~~with ~~under~~respect to the ~~Securities~~plan ~~Act,~~of ~~the~~distribution ~~information~~not ~~omitted~~previously ~~from~~disclosed in the ~~form~~registration ofstatement ~~prospectus~~or any ~~filed~~material aschange ~~part~~to ofsuch ~~this~~information in the registration statement in; ~~reliance~~provided, ~~upon~~however, ~~Rule~~that ~~430A~~paragraphs (1)(i), (1)(ii) and ~~contained~~(1)(iii) above do not apply if the information required to be included in a ~~form~~post-effective ofamendment ~~prospectus~~by those paragraphs is contained in reports filed with or furnished to the Securities and Exchange Commission by the registrant pursuant to ~~Rule~~Section ~~424(b)(1)~~13 or Section 15(4d) orof ~~497(h)~~the ~~under~~Exchange Act that are incorporated by reference in the ~~Securities~~registration ~~Act~~statement, ~~shall~~or beis ~~deemed~~contained toin bea ~~part~~form of ~~this~~prospectus ~~registration~~filed ~~statement~~pursuant asto ofRule 424(b) ~~the~~that ~~time~~is itpart ~~was~~of ~~declared~~the ~~effective~~registration statement.

(2) That, ~~For~~for the purpose of determining any liability under the Securities Act, each such post-effective amendment ~~that contains a form of prospectus~~ shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II(3) To remove from registration by means of a post-6effective amendment any of the securities being registered which remain unsold at the termination of the offering.

~~SIGNATURES~~ (4) That, for the purpose of determining liability under the Securities Act to any purchaser:

~~Pursuant~~(A) Each toprospectus ~~the~~filed ~~requirements~~by of the ~~Securities Act of 1933, the~~ registrant ~~has~~pursuant ~~duly~~to ~~caused~~Rule ~~this~~424(b)(3) ~~Registration~~shall ~~Statement~~be deemed to be ~~signed~~part onof ~~its~~the ~~behalf~~registration bystatement ~~the~~as ~~undersigned,~~of ~~thereunto duly~~the ~~authorized~~date in the ~~City~~filed ofprospectus ~~New~~was ~~York,~~deemed ~~State~~part of ~~New~~and ~~York,~~included onin ~~April~~the 4,registration ~~2025.~~statement; and

~~TENON~~(B) Each ~~MEDICAL~~prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, ~~INC.~~other ~~By:~~than ~~/s/~~registration ~~Steven~~statements relying M.on ~~Foster~~Rule ~~Steven~~430B M.or ~~Foster~~other ~~Chief~~than ~~Executive~~prospectuses ~~Officer~~filed in reliance on Rule 430A, shall be deemed to be part of and ~~President~~included ~~(Principal~~in ~~Executive~~the ~~Officer)~~registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

~~Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.~~II-7

Name	Position	Date
/s/ Steven M. Foster	Chief Executive Officer and President, Director	April 4, 2025
Steven M. Foster	(Principal Executive Officer)
/s/ Richard Ginn	Chief Technology Officer and Director	April 4, 2025
Richard Ginn
/s/ Kevin Williamson	Chief Financial Officer	April 4, 2025
Kevin Williamson
/s/ Richard Ferrari	Director	April 4, 2025
Richard Ferrari
/s/ Ivan Howard	Director	April 4, 2025
Ivan Howard
/s/ Kristine Jacques	Director	April 4, 2025
Kristine Jacques
/s/ Robert K. Weigle	Director	April 4, 2025
Robert K. Weigle
/s/ Stephen H. Hochschuler, M.D.	Director	April 4, 2025
Stephen H. Hochschuler, M.D.

~~II-7~~(i) Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424;

(ii) Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;

(iii) The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to any charter provision, by law or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

The undersigned registrant hereby undertakes that:

(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective.

(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

II-8

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Los Gatos, State of California, on June 22, 2026.

	Tenon Medical, Inc.

	By:	/s/ Steven M. Foster
		Steven M. Foster Chief Executive Officer and President (Principal Executive Officer)

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steven M. Foster and Kevin Williamson, or either of them, as his true and lawful attorneys-in-fact and agents, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments and any related registration statements filed pursuant to Rule 462 and otherwise), and to file the same with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents and full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent, or any substitute or resubstitute, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

Name	Position	Date

/s/ Steven M. Foster	Chief Executive Officer and President, Director	June 22, 2026
Steven M. Foster	(Principal Executive Officer)

/s/ Richard Ginn	Chief Technology Officer and Director	June 22, 2026
Richard Ginn

/s/ Kevin Williamson	Chief Financial Officer (Principal Financial Officer)	June 22, 2026
Kevin Williamson

/s/ Richard Ferrari	Director	June 22, 2026
Richard Ferrari

/s/ Ivan Howard	Director	June 22, 2026
Ivan Howard

/s/ Kristine Jacques	Director	June 22, 2026
Kristine Jacques

/s/ Robert K. Weigle	Director	June 22, 2026
Robert K. Weigle

/s/ Stephen H. Hochschuler, M.D.	Director	June 22, 2026
Stephen H. Hochschuler, M.D.

II-9

Filing Compare · Tenon Medical, Inc.